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Abstract Perhaps there is no more important issue in the
care of surgical patients than the appropriate use of mini-
mally invasive surgery (MIS) for patients with cancer.
Important advances in surgical technique have an impact
on early perioperative morbidity, length of hospital stay,
pain management, and quality of life issues, as clearly
proved with MIS. However, for oncology patients, histor-
ically, the most important clinical questions have been
answered in the context of prospective randomized trials.
Important considerations for MIS and cancer have been
addressed, such as what are the important immunologic
consequences of MIS versus open surgery and what is the
role of laparoscopy in the staging of gastrointestinal can-
cers? This review article discusses many of the key con-
troversies in the minimally invasive treatment of cancer
using the pro–con debate format.
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Perhaps there is no more important issue in the care of
surgical patients than the appropriate use of minimally
invasive surgery (MIS) for cancer patients. Important
advances in surgical technique have an impact on early
perioperative morbidity, length of hospital stay, pain man-
agement, and quality of life issues, as clearly proved with
MIS. However, for oncology patients, historically, the most
important clinical questions have been answered in the
context of prospective randomized trials. Important con-
siderations for MIS and cancer have been addressed such as
what are the important immunologic consequences of MIS
versus open surgery and what is the role of laparoscopy in
the staging of gastrointestinal (GI) cancers? Until recently,
the role of prospective randomized trials has been absent.
The era of landmark clinical trials for MIS and cancer
recently changed with the completion of the Clinical Out-
comes of Surgical Therapy (COST) trial, which randomized
872 patients with colonic adenocarcinoma to open versus
laparoscopically assisted colectomy. This landmark trial
demonstrated that the two groups were not signiﬁcantly
different in terms of local and overall survival at 3 years.
Similarly, the European Colon Cancer Laparoscopic or
Open Resection study group trial (CCLOR) compared
results for colon cancer between laparoscopic and open
surgery. There also was no difference between the two
groups with respect to morbidity and mortality. To date, the
long-term oncologic outcomes from the CCLOR trial have
not been reported. These trials have led the way for histor-
ical reconsideration of the utility of MIS surgery for cancer.
This symposium, entitled Minimally Invasive Surgery
and Cancer, presented at the Society of American Gastro-
intestinal and Endoscopic Surgeons (SAGES) annual
meeting in 2007, reviewed the important controversies
involved in the staging and treatment of gastrointestinal,
colorectal, hepatobiliary, and endocrine surgery. The
debate examines the most important topics, contrasting
technical considerations for MIS surgery used to treat adult
and pediatric esophageal, gastric, pancreatic, hepatic,
colorectal, and adrenal neoplasms. Speciﬁc topics debated
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DOI 10.1007/s00464-009-0583-3include Immunologic Differences Between Open and MIS
Cancer, Perioperative Morbidity and Mortality for MIS
Versus Open GI Cancer Surgery, The Role of Perioperative
Staging for Esophageal and Gastric Cancer, and various
MIS treatment methods for these disease sites.
The authors believe that this is the most comprehensive
compendium of controversial questions related to MIS and
gastrointestinal surgery to date. Although the debates form
the basis for important prospective randomized clinical
trials to answer these questions, signiﬁcant attention has
been directed toward evidenced-based data supporting the
diverse opinions put forth in the debates.
Finally, the debate questions arose from an important
project of the Research Committee of SAGES known as
the Delphi Project. This committee sought to ascertain the
most important MIS questions of concern to the members
of SAGES. Many of the most important questions that
members considered unanswered to date and of most
interest to the constituency were those related to the
appropriate use of MIS in cancer cases. As such, this
debate on MIS and cancer was conceived based on the
membership’s interest in the topic.
The controversy: do meaningful immunologic
differences exist between open and MIS cancer
surgery?
Pro: Immunosuppression in open oncologic surgery is
not a problem
Lawrence Wagman
Director of the Liver Tumor Program at City of Hope
Hospital, Duate, CA, USA
‘‘The world hates change, but it is the only thing that has
brought progress’’—Charles Kettering
‘‘Just because you can measure something, doesn’t mean
it amounts to anything’’—Anonymous
Many hypotheses exist regarding immunosuppression
and surgery:
1. There is an immunologic response to surgery.
2. The response with laparoscopy differs from that with
open surgery.
3. The differential response can be measured.
4. The impact of the differential can be measured.
5. The impact is ‘‘important.’’
What does important mean? It means that data are not
only statistically signiﬁcant, not just presentable, not just
publishable, or not just true in a murine model. It means
that data have real and human clinical signiﬁcance.
Important measurable indicators are overall outcome,
length of hospital stay, pain, infections, cost, local and
systemic recurrence rates, and survival rates. To prove any
of these hypotheses, studies must be prospective and ran-
domized, must have meaningful end points and blinding of
investigators, and must show statistical signiﬁcance and
present scientiﬁc (intellectual) consistency.
What effect does pneumoperitoneum have on the
inﬂammatory response? To date, most of the work in this
area has been done with animal models. In 2006, Fuentes
et al. [1] published a study showing a survival beneﬁt for
rats with carbon dioxide (CO2) pneumoperitoneum com-
pared with control animals at 48 h, with interleukin-6 (IL-
6) levels attenuated using a CO2 pneumoperitoneum. In
2004, Bachman et al. [2] demonstrated that CO2 insufﬂa-
tion reduces the inﬂammatory response in rats based on
reduced levels of alpha-2 macroglobulin mRNA and beta
ﬁbrinogen. Yet another rat model, described in a 2001
paper by Mendoza-Sagaon et al. [3] showed that a transient
suppression of delayed-type hypersensitivity (DTH) did not
occur in animals with a Nissen fundoplication performed
laparoscopically using CO2 pneumoperitoneum compared
with open control subjects.
The laparoscopic cholecystectomy that propelled lapa-
roscopyintothemainstreamintheearly1990swasthefocus
of numerous trials seeking an improvement in clinical vari-
ables [4]. In 1994, Steiner et al. [5] examined data from 34
hospitals in Maryland from 1985 to 1992. He reported a
declineinoperativemortalityfrom0.84to0.56overall,with
an odds ratio of 0.22 favoring the laparoscopic approach for
decreased mortality and with a 95% conﬁdence interval of
0.13to0.37.Amaincriticismofthisstudy,however,wasthe
heterogenicityofthecomparativepatientpopulations.Those
receiving the laparoscopic surgery were younger and had
less acute disease not as frequently complicated by common
bileduct(CBD)stones.Ahigherpercentageofthesepatients
were white and more likely to have health maintenance
organization (HMO) or private insurance.
Summary of studies
The response to sepsis is reduced in laparoscopic surgery,
both the inﬂammatory response and the ability to maintain
DTH [6].
A review of more than 10 articles shows no signiﬁcant
difference in wound, urinary, or lung infection rates
between the two approaches [7–10]. Although some ﬁnd-
ings suggest a higher rate of anastomotic leak with the
laparoscopic than with the open technique, this is most
likely explained by the learning curve and thus related to
operator experience. Earlier reports suggested slightly
higher local failure rates and higher port-site implantation
with laparoscopic oncologic surgery [8].
More recent studies currently demonstrate equivalent
rates for the colon and nearly equivalent rates for rectal
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factors [9, 10]. Numerous studies demonstrate equivalent
survival rates between laparoscopic and open cancer sur-
gery, although an occasional study shows beneﬁt for either
the laparoscopic or open approach.
In conclusion, laparoscopy is an excellent modern intra-
abdominal surgery technique for malignancy. Technical
aspects and operator skill deﬁne organs best addressed with
the laparoscopic versus the open technique. Using clinical
endpoints,itcanbeshownthatimmunologicfactorshaveno
role in the decision to perform these operations, with pref-
erence for open rather than laparoscopic procedure.
Con: Laparoscopic surgery for cancer reduces adverse
immunologic sequelae
Richard L Whelan
Associate Director of the Division of Surgical Oncology
at NewYork–Presbyterian Hospital/Columbia University
Medical Center, New York, NY, USA
Do meaningful immunologic differences exist between
open and MIS methods in the setting of cancer? I defend the
viewpoint that a measurable difference exists in the impact
on immune function in favor of laparoscopic methods.
However,fromtheoutset,itisimportantthatwebroadenthe
discussion to include surgery-related blood protein altera-
tions.Althoughsomeoftheseplasmacompositionalchanges
arelikelytohave animpactonimmunefunction,which may
in turn indirectly inﬂuence tumor growth or recurrence,
others are not immune system-related at all. Instead, these
‘‘other’’ alterations may have an impact on angiogenesis,
apoptosis, and tumor growth via other mechanisms. Fur-
thermore, although not immune system related, these other
sequelaemaybeofgreatimportance.Perhapsanotherwayto
phrase the initial question is to ask how open and MIS
methods inﬂuence the host’s ability to fend off tumor
recurrences and limit tumor growth after surgery. In addi-
tion, how does surgery inﬂuence tumor cells that remain in
the host’s bloodstream or tumor microfoci?
Findings show a growing list of parameters affected in
different ways by open and closed surgical techniques.
Harder than ﬁnding such parameters, however, is demon-
strating that the physiologic, immunologic, and other host
differences in response to surgery are important clinically.
The most challenging task has been, and still is, to establish
clinical relevance. In fact, in some cases, it is difﬁcult even
to determine whether a given change is ‘‘bad’’ or ‘‘good.’’
Immunologic consequences of the surgical approach
Before the laparoscopic era, it had been well established
that major open surgery is associated with temporary
suppression of a variety of cells involved with both innate
and speciﬁc immunity including lymphocytes, neutrophils,
monocytes, and macrophages. In addition, interactions
between cells and other cellular functions are negatively
inﬂuenced by open surgical trauma. Furthermore, the
ability to mount a positive response to a DTH recall antigen
challenge is suppressed after surgery [11–15].
The relative contribution of each part of an abdominal
procedure (abdominal wall access incision vs. intraab-
dominal dissection and resection) to the postsurgical
immunosuppression had not been assessed before the
advent of advanced laparoscopic methods. The results of
recent studies suggest that the method of entry into the
abdomen is an important determinant of postoperative
immune function.
For a variety of immune parameters, minimally invasive
methods are shown to be associated with a signiﬁcantly
better preserved function than equivalent open procedures.
Notably, in many cases, the differences are small and short
lived, on the order of a day and sometimes less, for several
variables. For a number of parameters, no differences have
been noted.
DTH testing One of the simplest methods for evaluating
immune function is DTH testing. The ability to mount a
DTH response to an intradermally injected antigen the
subject has previously encountered veriﬁes that several
important elements of the immune system are functioning,
namely, antigen presentation, proliferation of the memory
CD4 lymphocyte, cytokine elaboration, and the effector
response, which results in the wheal at the injection site. By
administering a series of DTH challenges, one before
(establishing the baseline response) and several after sur-
gery (compared with the preoperative result), it is possible
to assess the functional state of the immune system.
Animal studies have shown that laparoscopic cecectomy
is associated with signiﬁcantly better preserved DTH
responses than its open equivalent [16]. A small human
nonrandomized DTH study was conducted with colectomy
patients in the late 1990s. In this study, serial DTH chal-
lenges were given before and after surgery to both open
and closed colorectal resection patients. The study dem-
onstrated that open colectomy was associated with a sig-
niﬁcant decrease in the size of the mean DTH response
when patients were challenged on the day of surgery and
postoperative day (POD) 3, whereas the postsurgery
responses of the minimally invasive colectomy group were
not signiﬁcantly smaller than their preoperative results
[17]. A recently completed randomized human study that
assessed the impact of perioperative granulocyte-macro-
phage colony-stimulating activity (GM-CSF) in the setting
of minimally invasive colorectal cancer surgery has con-
ﬁrmed that there is no signiﬁcant decrease in DTH
response to tetanus or Candida on PODs 1 and 3 after
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results) [18].
Cytokines Surgical trauma evokes a potent local and
systemic inﬂammatory response manifested by rapid
changes in the plasma concentration of various acute phase
proteins and proinﬂammatory cytokines. Although
increased levels of cytokines and acute phase proteins
reﬂect an inﬂammatory response, they do not directly
correlate with the status of the immune system. Plasma
levels of acute phase proteins such as C-reactive protein
(CRP), the most widely measured marker of the acute
phase response, and the proinﬂammatory cytokines IL-1b,
IL-6, IL-8, and tumor necrosis factor-a (TNFa) typically
are transiently increased after signiﬁcant tissue injury.
Interleukin-6, the best studied cytokine, has consistently
been found transiently increased in response to injury.
Pre- and postoperative plasma levels of all the afore-
mentioned inﬂammatory mediators have been compared in
patients undergoing laparoscopic and conventional surgery.
Most reports on the stress response after open and lapa-
roscopic surgery have shown that open cholecystectomy is
associated with higher postoperative plasma levels of CRP,
TNFa, IL-1b, and/or IL-6 relative to laparoscopic chole-
cystectomy, suggesting that open surgery is associated with
a greater inﬂammatory response [19–23]. Signiﬁcantly
higher levels of some or all of these proteins also were
found postoperatively in patients after conventional Nissen
fundoplication [24, 25] and colorectal cancer resection than
in patients undergoing laparoscopic surgery [26–30]. Other
studies have shown that although both open and laparo-
scopic colorectal surgery are associated with elevated
plasma CRP levels, these levels return more promptly to
baseline preoperative values after laparoscopic than after
open surgery [31].
Speciﬁcally with regard to IL-6 levels, conﬂicting
results have been reported, although the discrepancy
between various studies may be the result of differences in
the sampling times. Investigators measuring IL-6 levels in
the ﬁrst 24 h after surgery have almost always found sig-
niﬁcantly higher levels in open surgery patients [27, 32–
34]. However, in a number of studies, the differences
between open and closed colectomy patients were lost
within 24 h. Several of the studies reporting no difference
between groups did not obtain the ﬁrst sample until at least
24 h after surgery [35].
Lymphocytes Studies assessing the number of circulating
lymphocytes of different subtypes have, with rare excep-
tion, found no signiﬁcant differences between open and
closed groups [31]. A randomized cholecystectomy study
that indirectly assessed the ratio of Th-1 to Th-2 lympho-
cytes by measuring levels of interferon c (Th-1) and IL-4
(Th-2) elaborated by peripheral blood monocytes in vitro
after stimulation found a signiﬁcant difference between the
laparoscopic and open groups only 2 h after the operation.
All other sampling points yielded similar results between
groups [36].
A recent colectomy study analyzed CD31 expression on
circulating T lymphocytes before and after surgery. Efﬁ-
cient killing of tumor cells or other pathogens depends,
among other things, on T-cell migration from the circula-
tion to peripheral tissues. T-cells migrating from the cir-
culation to the peripheral tissues express the CD31 antigen.
In the open group, CD31 expression was found to be sig-
niﬁcantly decreased from preoperative baseline levels on
the PODs 1 and 3. This was not the case in the laparoscopic
group. Furthermore, a signiﬁcant correlation was found
between the decrease in CD31 expression and the incision
length in the open group [37].
Some insight into the speciﬁc molecular effects of lap-
arotomy and laparoscopy on T-cells comes from a micro-
array analysis on the time course of the differential effects
of sham laparotomy versus CO2 pneumoperitoneum on
splenic T-cell gene expression in mice [28]. Relative to
anesthesia control, sham laparotomy 12 h after surgery
resulted in notable alterations (differences in expression in
398 T-cell genes more than twofold compared with 116
genes after pneumoperitoneum). At 24 h, the differences
between the two surgical methods were less marked, with
altered expression noted in 157 genes after laparotomy
versus 132 genes after pneumoperitoneum.
When global gene expression was compared between
laparotomy and pneumoperitoneum, the expression of 177
genes was increased after laparotomy relative to pneumo-
peritoneum at 12 h, a difference reduced fourfold at the 24-
h time point [38]. Functional differences in gene expres-
sion 12 to 24 h after surgery also were noted in both
groups. These transient but substantial alterations in splenic
T-cell gene expression proﬁles after laparotomy provide a
molecular basis for the observation that open surgery is
associated with transient but marked immune alterations.
Ongoing functional analysis of those genes with differen-
tial expression in response to laparotomy and pneumoper-
itoneum not only will uncover the biologic signiﬁcance of
these differences, but also may identify genes that can be
used as clinical markers of the effect surgery has on the
immune system.
Monocytes and macrophages Results regarding the in
vitro function of circulating monocytes and peritoneal
macrophages conﬂict and are difﬁcult to interpret.
According to some studies, CO2 pneumoperitoneum may
inhibit or downregulate peritoneal macrophage function.
However, in a rodent study comparing open and closed
cecectomy in the author’s lab demonstrated that open
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(a reﬂection of respiratory burst activity) from peritoneal
monocytes on POD 1 compared with anesthesia control
results. These results suggest that the peritoneal macro-
phages are less ready and able to function after open sur-
gery [39].
In a pig study that compared open and closed Nissen
fundoplication, Collet et al. [40] assessed the ability of the
peritoneal cavity to clear 10
9 Escherichia coli introduced
into the abdomen at the end of the operation. Bacterial
counts of peritoneal ﬂuid samples were taken 1, 2, and 8 h
after surgery. The open group bacterial count was dra-
matically higher than that of the closed group count 8 h
after the operation. However, the assessment in vitro after
recovery showed no differences in the ability of peritoneal
or circulating monocytes to phagocytize Staphylococcus
aureus between the open and closed groups.
A recently published large animal study of peritoneal
macrophages compared the impact of open, hand-assisted,
and laparoscopic nephrectomy on macrophage IL-6 and
TNF production [41]. Peritoneal macrophages were har-
vested 4, 12, and 24 h after surgery. These peritoneal
macrophages were cultured and then stimulated with
lipopolysaccharide, after which the levels of the afore-
mentioned cytokines were determined. All three types of
surgery were associated with increased TNF and IL-6
levels. However, the open nephrectomy group results at the
12- and 24-h time points were signiﬁcantly greater than the
results of the hand and laparoscopic groups, whose results
were similar [42]. These results imply that open methods
are associated with peritoneal macrophage activation to a
greater extent than MIS methods.
As the aforementioned three studies show, the literature
is conﬂicting with regard to peritoneal macrophages. Thus,
it is not clear what the ‘‘take-home’’ message is with regard
to peritoneal macrophages. Similarly, the clinical relevance
of these results, if any exists, is unknown.
With regard to peripheral blood mononuclear cells
(PBMCs), a randomized study of human colectomy
patients demonstrated a small but signiﬁcant difference in
expression of the human leukocyte antigen marker (HLA-
DR) on circulating monocytes in favor of the laparoscopic
patients on the POD 4 [27]. This is an activation marker for
monocytes. Decreased expression rates have been associ-
ated with a worse outcome for trauma patients.
Clinical import It should be realized that the clinical
signiﬁcance of the immune function differences, if any
exists, has not been determined. Better preserved postop-
erative cell-mediated immune function, in theory, may
have an impact on the rate of infections and possibly tumor
recurrence and survival rates. The low rate of port-site
wound infections noted for most laparoscopic procedures
and the signiﬁcantly better disease-free survival of lapa-
roscopic patients after colectomy for cancer noted by Lacy
et al. [43] in their randomized study seem to support this
notion.
Etiology of surgery-related immunosuppression What is
it about abdominal surgery that causes temporary sup-
pression of the immune system? Probably a number of
contributing factors are involved. Evidence shows that the
overall length of an abdominal wall incision is an important
factor. Some authors, considering the results of a murine
study, believe that the exposure of the abdominal cavity to
air is the cause of the immunosuppression after open sur-
gery. These latter investigators believe that small amounts
of lipopolysaccharide in the air cause immunosuppression
by stimulating bacteria in the intestine to elaborate lipo-
polysaccharide, which then translocates across the bowel
wall, after which it is absorbed systemically [44].
Possible future immunotherapies The controversy sur-
rounding laparoscopic surgery for cancer has led to studies
that have signiﬁcantly increased our understanding of
surgery’s impact on the body. This will hopefully lead to
new perioperative pharmacologic therapies that will lessen
the deleterious immunologic effects of all types of surgery.
This type of approach is exempliﬁed by administration of
immunostimulatory agents perioperatively to cancer
patients. Small animal studies have shown that such
treatment is associated with signiﬁcantly lower tumor
recurrence and metastases rates [45, 46]. Mels et al. [47]i n
a small randomized trial of 16 open surgery patients
demonstrated that seven perioperative doses of GM-CSF
was associated with signiﬁcantly better preserved postop-
erative DTH responses and HLA-DR expression on
monocytes than placebo. Usually, GM-CSF is used as a
bone marrow rescue agent in chemotherapy patients.
A similar randomized human study of perioperative
immunomodulation in the setting of colorectal cancer has
just been completed at Columbia University with a total of
59 patients [18]. In this study, GM-CSF was given daily
three times before surgery and then for the ﬁrst 4 postop-
erative days to patients undergoing MIS. The goal was to
upregulate immune function perioperatively and also to
determine the impact of this treatment. The drug was well
tolerated and not associated with any discernible compli-
cations. Unlike the Mels et al. [47] study mentioned earlier,
the Columbia study did not demonstrate signiﬁcantly better
immune function after GM-CSF treatment, as measured by
serial DTH responses, number of DR? monocytes, array of
Th1/Th2 cytokines, or plasma IFN-c levels.
One possible reason for these ﬁndings is that it may have
been much harder to demonstrate immune beneﬁts for the
GM-CSF group because the immune function of the control
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than in the open surgery control group of the Mels et al.
[47] study, which demonstrated more dramatic decreases in
the immune parameters followed. An unexpected and
noteworthy ﬁnding of this GM-CSF study was its clear
demonstration that GM-CSF results in signiﬁcantly higher
soluble vascular endothelial growth factor (VEGF)-recep-
tor 1 levels and a signiﬁcantly higher angiopoetin 1/an-
giopoetin 2 ratio on POD 5 than in the control group.
Furthermore, ﬁndings showed that post–GM-CSF blood on
POD 5 signiﬁcantly decreased endothelial cell proliferation
and invasion in in vitro cultures. These results suggest that
angiogenesis is inhibited by GM-CSF [18].
Another possible immunotherapy would be administra-
tion of preoperative tumor vaccines to encourage the
development of an active immune response against the
tumor before resection. Then, in the early postoperative
period, when the tumor burden is at its lowest, the patient
would have a means of eliminating any viable tumor cells
that may remain. In small animal studies, this approach has
been successful in lowering the rate of metastases [47]. To
the author’s knowledge, no human preoperative vaccine
trials are underway currently.
Surgery-related protein alterations
Not surprisingly, surgery has an impact on the composi-
tion of plasma, which contains a countless number of
different proteins. Because the bloodstream is ‘‘down-
stream’’ of all the body’s organs, it is difﬁcult to determine
the source or sources of the protein changes detected in
the plasma or serum. Furthermore, although some in vitro
data assess the impact of surgery-related plasma protein
alterations, it generally is difﬁcult to determine the clinical
signiﬁcance of many documented alterations. Whereas the
function and effects of most of the proteins assessed have
been well studied in vitro and, in some cases, in vivo, few
data exist regarding the import of temporary and some-
times modest changes in the plasma levels of these
parameters. Also, the precancer resection plasma levels of
some parameters (VEGF is a prime example) are shown to
be signiﬁcantly higher in cancer patients than in control
patients without tumors. High blood VEGF levels corre-
late with advanced disease stage and a worse prognosis.
Plasma VEGF levels increase after open and closed
colorectal resections and remain increased for at least
3 weeks (see later) [48].
Despite this very interesting ﬁnding, it has not been
established that this sustained increase has any bearing on
the oncologic outcome. Thus, similar to the situation with
the immune parameters, the burden of proof remains with
the laparoscopic enthusiasts to demonstrate clinical out-
come beneﬁts for the closed patients. The blood protein
alterations that may have an impact on tumor growth are
emphasized in this brief review.
Insulin-like growth factor-binding protein
Perhaps the best evidence, albeit in vitro data, regards
insulin-like growth factor binding protein-3 (IGFBP-3).
This well-studied protein has been shown to inhibit tumor
growth via several mechanisms. Besides binding and
essentially ‘‘tying up’’ insulin-like growth factor (IGF)-1, a
major cell growth factor (an indirect effect), IGFBP-3 also
induces apoptosis in most tumor cell lines. This protein
also inhibits DNA synthesis in poorly differentiated cell
lines. Thus, IGFBP-3 is an endogenous inhibitor of tumor
growth. At baseline, the vast majority of people have fairly
high levels of this protein. Notably, only the intact protein
has the tumor inhibitory effect. In contrast, the partially
degraded IGFBP-3 protein does not have this effect.
Major abdominal surgery, in open more than in lapa-
roscopic surgery, is associated with a 1–3-day signiﬁcant
decrease in plasma levels of intact IGFBP-3 [49]. In the
laparoscopic patients, a nonsigniﬁcant decrease was
observed. The duration of the larger decrease in the open
surgery patients was associated with the incision length.
Furthermore, POD 1 plasma (with decreased intact IG-
FBP-3 levels) from open colectomy patients has been
shown to stimulate in vitro tumor cell growth compared
with culture results obtained when preoperative plasma
from the same patients is assessed. The fact that when
exogenous IGFBP-3 is added to the postoperative plasma
no increase in the in vitro tumor growth rate over baseline
is observed suggests that the decrease in IGFBP-3 levels is
responsible for the tumor growth stimulation noted with the
‘‘raw’’ postoperative plasma [50].
Matrix metalloproteinase-9
Several of the matrix metalloproteinases (MMPs) are
thought to play an important role in tumor growth and
spread. Findings have shown plasma MMP levels to be
elevated in patients with a variety of different cancers.
These proteolytic enzymes are capable of degrading con-
nective tissue at the border of tumors, thus permitting the
spread and growth of the tumor in question. In the plasma,
MMP-9 has been demonstrated to degrade IGFBP-3 and is
thought to be the mechanism by which open surgery results
in a decrease in IGFBP-3 levels.
In a study of 88 open and closed colorectal cancer
patients, a signiﬁcant increase in plasma MMP-9 levels was
noted on POD 1 in the open group, whereas no sizable
change in the laparoscopic group’s levels occurred. The
decrease in MMP-9 levels is very transient, and by PODs 2
and 3, the levels have returned to normal [51].
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The most likely reason why the preceding noted MMP-9
decrease is so short lived is that plasma tissue inhibitor of
metalloproteinase-1 (TIMP-1) level also rises after open
surgery and remains signiﬁcantly elevated over baseline for
at least the ﬁrst 3 days after surgery. Laparoscopic patients
manifest a smaller yet still signiﬁcantly increased TIMP-1
level after surgery [51].
Similar to the situation with the MMPs, ﬁndings have
shown TIMP-1 levels to be elevated in the setting of sev-
eral different cancers. The clinical import of these transient
increases is uncertain.
VEGF
As a potent inducer of angiogenesis, VEGF is critical for
wound healing and plays a crucial role in the early steps of
angiogenesis. It is logical to anticipate that plasma levels
increase after major surgery. In addition, VEGF has been
shown to facilitate and promote tumor growth. Findings
have demonstrated that many tumors, including colonic
adenocarcinoma, cannot grow beyond 2 to 3 mm without
the development of new blood vessels.
When groups of cancer patients have been evaluated
before resection, ﬁndings have shown their mean serum
and plasma VEGF levels to be signiﬁcantly higher than the
mean levels of control populations without tumors [52–54].
The height of the elevation for some tumors, including the
colon, correlates with the stage of disease or prognosis in
some series.
What impact does surgery have on blood VEGF levels?
A postoperative increase in plasma VEGF levels may
facilitate tumor growth early after surgery. In a study
published in the fall of 2008, early postoperative plasma
VEGF levels were studied in the setting of both open and
minimally invasive colorectal resection for cancer and for
benign indications. In the open cancer patients, a signiﬁ-
cant and stepwise increase was noted on PODs 1 and 3
compared with preoperative levels. In the laparoscopic
patients on POD 3, a signiﬁcant VEGF increase over
baseline value also was noted. Notably, however, the mean
laparoscopic value, although increased, was signiﬁcantly
lower than that noted in the open group at the same time
point. Also, no increase was noted on POD 1 in the closed
group. Although the benign colorectal resection patients’
baseline VEGF levels were lower than those of the cancer
group, their response to surgery was very similar, showing
a steady increase in the open group and a delayed and
blunted increase in the laparoscopic group.
A more recent study assessed plasma VEGF levels
during the ﬁrst postoperative month after laparoscopic
colorectal resection for benign (30 patients) and malignant
(49 patients) disease. In the cancer patients, VEGF levels
continued to rise, peaking during postoperative week 3.
Signiﬁcant elevations were noted from POD 3 through
postoperative week 4. Similar yet lower and less persistent
elevations were noted in the patients with benign disease
(values peaked during the second week) [48]. To the
author’s knowledge, this is the ﬁrst surgery-related plasma
protein alteration to date demonstrated to persist for this
length of time. Given the fact that these were minimally
invasive patients, the ﬁndings came somewhat as a sur-
prise. Whether levels for open colorectal resection patients
would be similar remains to be shown. In the author’s
view, although it is possible that open surgery patients will
manifest even greater plasma VEGF elevations, it is more
likely that these patients will demonstrate similar eleva-
tions. Thus, the transient 1–2-day delay in VEGF increase
observed after closed surgery may be of little signiﬁcance
considering the long duration of the effect.
Angiopoetin 1 (Ang 1) and angiopetin 2 (Ang 2)
These proteins play important yet conﬂicting roles with
regard to VEGF-mediated angiogenesis. Both bind to the
Tie-2 receptor. Whereas Ang 1 stabilizes mature vessels
and inhibits VEGF-mediated angiogenesis, Ang 2 is
thought to encourage and promote VEGF-mediated angi-
ogenesis. The ratio of plasma Ang 1 to Ang 2 levels is
thought to be a measure of the body’s tendency toward
VEGF-mediated angiogenesis. A high ratio would
encourage blood vessel stabilization, whereas a low ratio
would favor the VEGF-stimulation effects that stimulate
new vessel formation.
A study investigating the benign pathology of open and
closed colon and rectal resection patients demonstrated that
both surgical methods are associated with a decrease in
Ang 1 and an increase in Ang 2 levels on PODs 1 and 3
such that a signiﬁcantly greater Ang 1/Ang 2 ratio was
noted at both time points. The magnitude of the Ang 2 and
Ang 1/Ang 2 ratio changes was signiﬁcantly greater in the
open resection group [55].
A recently completed study of more than 100 colorectal
resection patients demonstrated that after either open or
minimally invasive resection (on both PODs 1 and 3), Ang
1 levels were signiﬁcantly lower and Ang 2 levels signif-
icantly higher compared with the preoperative results for
both benign and cancer indications. Similarly, the Ang 1/
Ang 2 ratio on PODs 1 and 3 after both types of surgery
was signiﬁcantly lower, favoring VEGF-mediated angio-
genesis. Although both surgical methods had similar
effects on Ang 1, Ang 2, and the Ang 1/Ang 2 ratio, the
extent of the changes (decrease in Ang 1, increase in Ang
2, and decrease in the Ang 1/ Ang 2 ratio) was signiﬁcantly
greater after open colorectal resection. Thus, surgery in
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has a notably greater impact [56].
Summary of studies
Clearly, MIS is associated with fewer marked perturbations
of the immune system. It makes sense that it is desirable to
maintain baseline immune function and status. Thus, lap-
aroscopic surgery is preferable to open methods from this
vantage point. Better clinical data are needed with regard to
short- or long-term outcome measures that demonstrate
advantages for the MIS patients. Lower wound infection
and morbidity rates have been reported by some investi-
gators. These may be the clinical reﬂection of better pre-
served immune function. The shorter hospital stay also may
be related in some way. However, this has not been proved
and would be hard to demonstrate.
The controversy: does MIS surgery have advantages for
the perioperative management of cancer patients?
Pro: Perioperative complications and length of hospital
stay are reduced with MIS cancer surgery
Christopher Schlachta
Associate Professor of Surgery and Oncology, Schulich
School of Medicine and Dentistry, Ontario, Canada
It has been nearly a quarter century since Karl Semm
performed the ﬁrst laparoscopic appendectomy and
20 years since Muhe and Mouret heralded the modern era
of MIS. The early promise of smaller scars, less pain, fewer
complications, and shorter hospital stay that accompanied
the introduction of laparoscopic cholecystectomy led to
nearly every operation in the abdominal cavity being
described in some laparoscopic fashion (and currently with
robotics). The beneﬁts of the laparoscopic approach seem
to vary according to the type of procedure, with some
procedures showing clear advantages over open surgery,
and others showing more moderate improvements.
One thing is clear. Minimally invasive surgery directly
and indirectly changed the way we think about surgery and
the way we care for our surgical patients. This latter point
may lead to the most indisputable argument supporting this
resolution. When perioperative complications that may be
avoided by laparoscopy were considered, the natural early
inclination was to study pulmonary function and recovery.
Evidence from randomized trials of open versus laparo-
scopic cholecystectomy have clearly demonstrated less
impairment and more rapid recovery of pulmonary func-
tion after the laparoscopic approach. This has been repli-
cated with other surgeries including colon surgery.
However, because perioperative pulmonary complications
are fairly infrequent, most trials have been underpowered
and unable to detect a signiﬁcant advantage for
laparoscopy.
One clear advantage of MIS is the smaller scars that
result. Many have paternalistically dismissed the cosmetic
advantages of smaller scars but have overlooked the very
signiﬁcant impact that small scars have on postoperative
wound complications. Several procedures including lapa-
roscopic appendectomy [57], colectomy [58–60], and
gastric bypass [61] boast level 1 evidence of reduced
wound infections with laparoscopy. Findings have further
shown that laparoscopic gastric bypass [61] and colectomy
[62] are associated with a lower incidence of incisional
hernia formation. The latter study from the Cleveland
Clinic, albeit retrospectively, also found a signiﬁcant
reduction in hospital readmission for small bowel
obstruction with laparoscopy and a 51% reduction in the
requirement of reoperation for these two complications. To
compound this issue further, one study found fewer post-
operative wound complications associated with laparo-
scopic repair of ventral hernias, presumably arising from
prior open surgery [63].
Perhaps most compelling is the recent metaanalysis
investigating trials of laparoscopic versus open colectomy
by Tjandra and Chan [60]. This metaanalysis reported on
17 prospective randomized clinical trials involving more
than 4,000 procedures. It found a reduction in perioperative
mortality associated with laparoscopy.
The overall length of hospital stay is the other closely
scrutinized advantage of laparoscopic surgery. Once again,
the beneﬁts are clear with some procedures such as lapa-
roscopic cholecystectomy [64], bariatric surgery [61], and
antireﬂux surgery [65]. The gains with laparoscopic
colectomy have been more moderate, leading some to
question the magnitude of this advantage. Three metaa-
nalyses investigating prospective randomized trials of
laparoscopic versus open colon surgery all conclude that
the highest-level evidence shows laparoscopic colon sur-
gery to be comparable with open surgery, leading to a
signiﬁcant reduction in postoperative hospital stay [58–60].
It might then be asked why any debate exists regarding
the clear advantage of laparoscopic surgery in terms of
hospital length of stay. This debate arises from the
expanding body of work surrounding ‘‘fast-track’’ surgery.
It is clear that by modifying the perioperative care we
deliver to our patients, by minimizing pain and other fac-
tors that incite the surgical stress response, and by releasing
our patients from the shackles of unnecessary tubes and
drains, we can mitigate the trauma of surgery and reduce
the need for hospitalization. Laparoscopic surgery is just
one very effective component of this multimodal care, and
patients having laparoscopic procedures also can beneﬁt
from these interventions.
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have been supplanted by ‘‘fast-track’’ protocols has come
from one randomized trial of 60 patients who underwent
laparoscopic and open colon surgery. It was reported that
the median lengths of hospital stay between the two groups
were not signiﬁcantly different [66]. Although this was
clearly a provocative effort and the only truly double-
blinded trial conducted to date, a number of methodologic
concerns surround the design and analysis of this trial that
call signiﬁcantly into question the validity of its ﬁndings.
There also was a high hospital readmission rate (29%).
Most important, despite assurances that discharge criteria
were the same between groups and that patients, nurses,
and physicians were blinded to the type of operative pro-
cedure, nurses still were able to guess which patients had
undergone laparoscopy, and both patients and their rela-
tives in the open surgery group were more likely to feel
they were pushed out of the hospital too quickly. This
alone suggests that no amount of fast tracking is going to
invalidate the advantages of laparoscopy.
The ﬁnal point that comes to fore is simply this: no one
ever cared about the length of hospital stay before MIS
threatened the status quo. That we are even debating the
advantages of laparoscopy in light of recent efforts in
‘‘fast-track’’ care is solid proof of the indisputable effect
laparoscopic surgery has on reducing the length of hospital
stay.
Con: Perioperative complications and length of hospital
stay are equivalent for open and MIS cancer
Richard P. Billingham
Clinical Professor, Department of Surgery, University of
Washington, Seattle, Washington
Is laparoscopic surgery, in fact, good enough to replace
open surgery? Are current laparoscopic techniques as good
as it is going to get? Does the size of the incision really
matter? These were some of the fundamental questions
debated in the surgical literature as laparoscopic surgery
became not only a reality but also an option more fre-
quently demanded by patients.
As an example, advantages quoted for laparoscopic
colectomy include less pain, earlier resumption of GI
function, shorter hospital stay, fewer complications, less
interference with immune functions, and the fact that it is
‘‘feasible and safe.’’ It also is said that because of these
advantages, ‘‘the public demands it.’’ Recent ﬁgures for
length of hospital stay in papers published over the past
12 months are 5 to 8 days after laparoscopic colectomy. It
is rare to ﬁnd a quoted hospital stay shorter than 4 days,
which is the commonly quoted length of stay for open
surgery if critical pathways are used. Interestingly, when
length of hospital stay ﬁgures are quoted for laparoscopic
colectomy patients, these patients typically have been
treated differently from open colectomy patients in the
same study, and the two groups have not been subjected to
a similar ‘‘critical pathway’’ or ‘‘fast track.’’
An important paper from Basse [66] appearing in March
2005 reported a randomized blinded trial of 60 patients
older than 55 years. All these patients had elective right or
sigmoid resections, epidural anesthesia, and anastomoses
more than 12 cm from the anus, but patients and observers
were both blinded to the type of surgery used for each
patient. This meant that the physicians making their rounds
for the patient after surgery were not the ones to inspect the
incision and were not privy to information about whether
the patient had laparoscopic or open colectomy. In this
study, the operative time was about 50% longer for the
laparoscopic surgery, but importantly, patients with an open
procedure had a shorter hospital stay (2.3 vs. 2.9 days). In
addition, the laparoscopic patients had a higher pain score
than those undergoing open surgery. No difference was
found in GI function, cardiopulmonary function, mental
function, CRP levels, convalescence, or patient satisfaction.
Similar trials and results were found by King et al. [67]
from the United Kingdom in March 2006 and by MacKay
et al. [68], with essentially no difference in mean hospital
stay between the laparoscopic and open groups. The
shortest hospital stay reported in the paper by King was
5.2 days, which is comparable with that seen using critical
pathways for open surgery in the United States.
Postoperative complications and outcomes have been
compared in many papers. The metaanalysis of Abraham
et al. [59] published in 2004 that included 2,512 patients
from 12 randomized control studies showed no signiﬁcant
reduction in overall morbidity rate with laparoscopic ver-
sus open surgery. The only difference found in local
complications was that wound infection rates were twice as
high for open versus laparoscopic cases, but these studies
were uncontrolled for the use of wound protectors and 34
other factors known to reduce the incidence of wound
infection.
In the MRC CLASICC trial 5 reported in May 2005,
mortality after open surgery was reported to be 5% com-
pared with only 1% after laparoscopic surgery [69].
However, in this study, 29 patients required conversion,
and the mortality rate for the patients in this group was 9%,
even higher than had the patient undergone open surgery
initially. In this study, no differences were found in terms
of intraoperative complications, 30- or 90-day postopera-
tive complications, 7-day transfusion requirements, or
quality-of-life scores. Interestingly, the authors stated that
‘‘impaired short-term outcomes after laparoscopic-assisted
anterior resection for cancer of the rectum do not yet justify
its routine use.’’ In the COLOR trial reported in 2005 [70],
no difference was noted in terms of morbidity or mortality,
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care.
The most recent metaanalysis, published by Noel et al.
[71] in February 2007 found 88 comparisons of MIS with
open surgery. These authors narrowed this down to what
they believed were more comparable trials. Only 22 of
these studies were, in fact, randomized controlled trials. No
difference was seen in terms of perioperative mortality, and
with perioperative morbidity, the wound infection rate was
2.9% for the laparoscopic cases compared with 4.4% for
the open cases. The open group showed a slightly higher
incidence of respiratory problems (1.0% vs. 1.6%), but no
other signiﬁcant differences. The mean length of hospital
stay after laparoscopic surgery in these groups was
7.8 days compared with 11.6 days for open surgery.
However, again, none of the studies was controlled for
perioperative care.
Another review, published in August 2006 by Reza et al.
[72] also found no signiﬁcant differences in the incidence
of complications or postoperative mortality, but did
observe that the time required for laparoscopic colectomy
was signiﬁcantly longer. These authors also noted no sig-
niﬁcant differences in overall mortality, cancer-related
mortality, or disease recurrence.
Conversions remain an ongoing problem, and rates
typically are in the 15% range. A consequence of conver-
sion is that morbidity and mortality are greater in the
converted group than for patients who undergo open sur-
gery initially. Marusch et al. [73] in 2001 found appre-
ciably poorer results after conversion, and Senagore et al.
[74] in 2003 noted that the average length of hospital stay
triples for patients who have undergone conversion. In the
study by Moloo et al. [75] in May 2004, 11 converted
patients had a 12% absolute decrease in survival at 2 years
and a 7.8% absolute decrease in survival at 5 years.
The advantages of open colectomy include versatility,
speed, efﬁciency, a shorter learning curve, lower cost, and
greater safety. The disadvantages of open colectomy would
seem to be immunologic indicators, although the signiﬁ-
cance of the ﬁndings in this ﬁeld is completely unknown.
Certainly, no difference is found between open and lapa-
roscopic surgery in duration of postoperative ileus, time
until resumption of oral feeding, or length of hospital stay
when critical pathways are used. There may be a slight
increase (1%) in the wound infection rate, but with modern
methods of treating wound infections, this generally does
not involve any additional hospital stay or expense.
In November 2005, Dr. Robin Macleod [76] noted that
from a Canadian perspective, cancer results are similar. No
difference is found in quality of life, pain, or discharge
times, and there are signiﬁcant concerns about costs and
training. In September 2006, Cecil et al. [77] noted a high
rate of anastomotic leakage with laparoscopic surgery,
quoting papers by Morino et al. [78] in 2003 and Leroy et al.
[79] in 2004, both of which showed anastomotic leak rates
in the 20% to 25% range, concluding that all laparoscopic
rectal cancers should be defunctioned. These authors also
note that ‘‘one of the main advantages of laparoscopic
colorectal surgery, namely, earlier mobilization and dis-
charge, has been difﬁcult to demonstrate with laparoscopic
rectal resection.’’ In Dr. Rattner’s [80] presidential address
for SAGES in April 2005, he states: ‘‘We must move
beyond laparoscopic surgery if we are to remain relevant.’’
In summary, open colectomy still is preferred in most
cases because of its versatility, speed, efﬁciency, shorter
learning curve, less morbidity, greater safety, and lower
cost. It is highly questionable whether the difference in
incision size makes any clinical difference, and it probably
is more important to know what to do than to debate about
whether to perform it with open or laparoscopic procedure
or how long the incision should be. The reasons for
avoiding laparoscopic colon surgery are that it offers
increased cost but minimal or no advantage to the patient,
either oncologically, in terms of perioperative care, or for
quality of life.
The controversy: what is the role of perioperative
staging for esophageal and gastric cancer?
Pro: Endoscopic ultrasound and MIS staging play an
integral role in the management of primary esophageal
and gastric cancer
Jeffrey Ponsky
Professor and Chairman in the Department of Surgery at
Case Western Reserve University School of Medicine,
Cleveland, OH
In Western countries, esophageal and gastric cancers
have been increasing in incidence and prevalence over
several decades. Both cancers generally have a poor
prognosis. The 5-year survival rate for esophageal cancer
approximates 15%, and the overall 5-year survival rate for
gastric cancer is 15% to 20%, although up to 60% of
patients with localized lesions have long-term survival.
Staging plays two integral roles in the management of
esophageal and gastric cancer: to detect potentially curable
patients and to avoid nontherapeutic laparotomy for those
who have incurable disease [81]. Standard staging methods
for esophageal and gastric cancer include computed
tomography (CT) and positron emission tomography (PET)
scans.Bothareaccurateindetectinggrossmetastaticdisease
but may miss subtle lymph node metastases. Furthermore,
standard imaging cannot adequately assess tumor (T) stage
in the tumor node metastasis (TNM) classiﬁcation [82]. To
that end, endoscopic ultrasound (EUS) and MIS
Surg Endosc (2010) 24:304–334 313
123(thoracoscopy and laparoscopy) have been instituted for
accurate staging of esophageal and gastric cancers. Both
EUS and MIS are vital components of staging, directing
appropriate therapy to patients with gastric or esophageal
cancer.
EUS in esophageal cancer
In esophageal cancer, T1–T3 lesions are considered oper-
able and resectable. In esophageal cancer, EUS is the most
accurate means of determining T-stage [83]. Endoscopic
ultrasound displays ﬁve distinct layers of the esophageal
wall, namely, the echo/superﬁcial mucosa boundary, the
mucosa, the submucosa, the muscularis propria, and the
adventitia. As shown by pathology specimens, the sensi-
tivity of EUS for T-staging is 85% to 90%, far exceeding
that of other available imaging methods.
Patients with advanced locoregional disease may beneﬁt
from neoadjuvant therapy before surgery. Endoscopic
ultrasound has the capability to detect regional lymphad-
enopathy and to sample suspicious lymph nodes by ﬁne-
needle aspiration. The characteristics of suspicious lymph
nodes include size larger than 8 to 10 mm, sharp demar-
cation from the surrounding fat, hypoechoic density, and
rounded shape. The sensitivity of EUS in detecting lymph
node involvement compared with pathology is approxi-
mately 70% [82]. The diminution in sensitivity results from
the difﬁculty in deciphering benign from malignant ade-
nopathy and sampling errors from ﬁne-needle aspiration.
Involvement of the celiac nodes in esophageal cancer is
considered to be metastatic disease. Endoscopic ultrasound
is the most accurate method for evaluating the celiac lymph
nodes. Moreover, EUS may add prognostic value for
patients receiving neoadjuvant therapy by assessing the
local response after treatment [84].
EUS in gastric cancer
Endoscopic ultrasound displays a resolution of 0.1 mm
when imaging the gastric wall. Therefore, EUS is highly
accurate in determining T-stage in early gastric cancers.
Gastric EUS shows ﬁve hypoechoic levels with corre-
sponding histologic layers: the water-superﬁcial mucosa
barrier, the deep mucosa, the submucosa, the muscularis
propria, and the serosa and subserosal fat. The use of a
high-frequency probe (20 MHz) may improve detection of
early tumors, whereas a low-frequency probe (7.5 MHz)
allows better visualization of advanced tumors [85].
Tumors conﬁned to the ﬁrst three EUS layers are consid-
ered T1 lesions. For such lesions, EUS has shown accuracy
up to 100%. Overall accuracy for T-staging is 80%, and
more advanced tumors obscure echoendoscopic images
because of accompanying ﬁbrosis and inﬂammation [82].
Assessing regional lymph node involvement is possible
with EUS. The accuracy of nodal staging is 60% to 65%,
with higher accuracy achieved when ﬁne-needle aspiration
is implemented. Although often technically challenging,
EUS interrogation for regional lymphadenopathy provides
important prognostic information.
Endoscopic ultrasound also offers the capability for
assessing metastatic disease in gastric cancer. Most of the
liver’s left lobe can be evaluated with the EUS probe
positioned near the esophagogastric junction. Moving the
probe to the distal stomach and bulb of the duodenum
permits visualization of part of the liver’s right lobe. In one
study, EUS was able to detect unsuspected liver metastases
(i.e., those that evaded CT detection) in 7% of gastric
cancer patients [86].
MIS for esophageal cancer
Thoracoscopy and laparoscopy are considered comple-
ments to standard staging for select patients with esopha-
geal cancer. Thoracoscopy through the right hemithorax
allows visualization of the upper two-thirds of the thoracic
esophagus and aortopulmonary nodes, whereas the lower
esophagus is investigated through the left chest.
Nodes can be sampled thoracoscopically using standard
techniques. These techniques have shown accuracy for
lymph node involvement ranging from 80% to 95%, as
shown by pathology specimens. Due to the lack of sensi-
tivity of EUS, CT, and PET, MIS techniques may change
staging in up to 40% of patients with esophageal cancer.
Laparoscopy may have utility for patients with cancers
of the esophagogastric junction. Using a three-port tech-
nique, the entire peritoneum can be searched for implants,
the lesser sac can be entered for examination of the celiac
nodes, and the liver can be inspected [87]. Additionally,
feeding jejunostomies can be placed using laparoscopic
techniques in patients found to harbor metastatic disease.
Laparoscopy is recommended for patients with
advanced stages of esophageal cancer detected by con-
ventional imaging. Thoracoscopy should be used selec-
tively for patients with lesions in the mid esophagus.
MIS for gastric cancer
For staging gastric cancer, CT scanning has a sensitivity
considerably less then 100%. Patients with small-volume
metastatic disease have life expectancies of 6 to 9 months.
To spare nontherapeutic laparotomies, laparoscopic staging
is indicated for surgical candidates with locally advanced
disease but no evidence of metastases [87].
Laparoscopic staging is not needed for T1 lesions
because they should go directly to deﬁnitive operation. An
extensive laparoscopic examination is performed in the
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ined. The surface of both the right and left liver lobes is
inspected. The root of the mesentery is examined for local
invasion. The lesser sac is entered for visualization of the
celiac plexus and the caudate lobes of the liver.
Laparoscopic staging in gastric cancer detects CT-occult
metastatic disease in up to 40% of patients. Irrigation of the
peritoneum, with cytologic examination of the aspirate,
may increase the detection of metastatic disease. In most
studies, laparoscopic staging spares nontherapeutic lapa-
rotomy for one-third of gastric cancer patients. Less then
10% of these patients subsequently require laparotomy for
palliative measures.
Conclusion
Both EUS and MIS provide critical staging information in
cases of esophageal and gastric cancer and serve to restrict
nontherapeutic operations in patients with a limited life
expectancy. Endoscopic ultrasound for esophageal cancer
and laparoscopy for advanced gastric cancer should be con-
sideredstandard,whereasEUSforgastriclesionsandMISfor
esophageal cancer should be applied for select patients.
Con: Preoperative staging may not alter the
management of primary esophageal and gastric cancer
Mitchell C. Posner
Chief of the Section of General Surgery and Surgical
Oncology at the University of Chicago
The management of esophageal and gastric cancer has
evolved considerably over the past decade. Signiﬁcant tech-
nological advances have been applied to the diagnosis and
staging of both esophageal and gastric cancer. Emerging
technologies in imaging and endoscopic/laparoscopic meth-
ods have substantially improved our ability to stage patients
accurately before therapeutic interventions. Further reﬁne-
ments instaging are being explored currently as investigators
applytechniquesinmoleculargeneticsthatlikelywillprovide
aunique‘‘ﬁngerprint’’fortailoringtherapytoeachindividual
patient. However, the most signiﬁcant breakthroughs in the
overall management of patients with esophageal and gastric
cancer have involved the area of therapeutics, in which a
‘‘new’’ paradigm exists. This paradigm has at its core the
explicit understanding that tumor biology, not staging, dic-
tates treatment response and outcome.
The biology of esophageal cancer is best illustrated by
the sobering fact that the number of deaths from esopha-
geal cancer in the United States is nearly equivalent to the
number of new cases diagnosed each year [88, 89].
Therefore, the concept of ‘‘early’’ esophageal cancer does
not reﬂect reality for the population of patients treated in
this country. Results from the National Cancer Data Base
on esophageal cancer identify only 14% of patients
receiving a diagnosis of stage 1 disease at presentation
[90]. It is important to note that only 63% of patients
classiﬁed as having ‘‘early’’ esophageal cancer will not
experience recurrence within the ﬁrst year from the start of
treatment. Therefore, the term ‘‘early-stage esophageal
carcinoma’’ is a misnomer because the vast majority of
patients have either occult regional (lymph node) or distant
disease at the time of presentation.
Overall 5-year survival rates have increased over the
past three decades, from a low of 5% in the 1970s to 15%
in the 1990s [91]. This improvement, although modest at
best, can to a great extent be attributed to the therapeutic
paradigm shift toward neoadjuvant chemotherapy/
chemoradiotherapy.
A substantial body of evidence now exists to support the
use of preoperative chemotherapy or chemoradiotherapy
before resection. The results from prospective randomized
trials demonstrate an improvement in survival favoring
patients who receive preoperative therapy rather than sur-
gery alone [92, 93]. Substantial downstaging has been
observed regardless of the documented stage at presenta-
tion, and the survival of patients who do respond is sub-
stantially better than that of patients who do not respond.
Recent reports of trials examining the role of PET scans to
assess early metabolic response conﬁrm that biologic
behavior, not staging, may be the most important predictor
of response to treatment and eventual outcome. Fluorode-
oxyglucose (FDG)-PET imaging 2 weeks into the course of
preoperative chemotherapy reliably predicts response to
induction chemotherapy, correlates with improved sur-
vival, and for patients identiﬁed as nonresponders, allows
for a treatment change in the form of an alternative che-
motherapy regimen or surgical intervention [94, 95].
In summary, the overwhelming majority of patients with
esophageal carcinoma present with advanced disease,
whereas a substantial number of patients with ‘‘early’’-
stage carcinoma of the esophagus harbor occult metastatic
disease. In both instances, staging does not and should not
alter the therapeutic approach demonstrated to improve
outcome. Neoadjuvant chemotherapy/chemoradiotherapy
effectively downstages both early and advanced tumors,
and the biologic response, as measured by surrogates such
as FDG-PET, may be more predictive of successful treat-
ment than the extent of disease at the time of diagnosis.
As with esophageal cancer, the vast majority of patients
with gastric adenocarcinoma have locally advanced disease
at the time of their initial presentation. National Cancer
Data Base results demonstrate that only 9% of patients
present with stage 1a (T1, N0) disease [96]. The 5-year
survival rate in the United States for stage 1a disease is
only 78%, with a substantial dropoff in 5-year survival for
higher-stage disease: 58% for stage 1b, 34% for stage 2,
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(surgery alone) of a prospective randomized trial examin-
ing the value of perioperative chemotherapy in resectable
gastroesophageal cancer conﬁrms that a minority of
patients (8.3%) present with T1 gastric carcinoma [97, 98].
Preoperative staging would have value only if therapy was
altered based on staging information. The results from this
randomized trial (MAGIC) of perioperative chemotherapy
versus surgery alone suggest that staging inﬂuences prog-
nosis but not treatment.
The MAGIC trial demonstrates a signiﬁcant improve-
ment in both progression-free and overall survival favoring
the patients who received perioperative chemotherapy for
resectable carcinoma of the stomach, esophagogastric
junction, or lower esophagus [89]. Patients randomized to
the perioperative chemotherapy arm of the study compared
with those who underwent surgery alone had a tumor in the
resected specimen with a smaller maximum diameter, a
greater proportion of T1 and T2 tumors, and less advanced
nodal disease. These data suggest that regardless of T or N
stage, all patients derive some beneﬁt from current che-
motherapy regimens, in this instance delivered both before
and after surgical resection.
Advanced technology staging tools have a central role in
the overall assessment of patients with esophageal and
gastric cancer. They provide essential information that
deﬁnes the extent of disease, has the potential to stratify
patients for treatment, and most importantly, is used in
clinical trials designed to examine novel therapeutic
approaches. Unfortunately, because less than 2% of patients
in the United States enter clinical trials, the utility of staging
for this most critical task is negated. Furthermore, the
overwhelming majority of patients in the United States have
advanced disease at the time of presentation, and in this era
of effective neoadjuvant therapy, it could be argued that all
patients regardless of stage derive some beneﬁt from an
aggressive approach to upper gastrointestinal cancer.
Finally, the cost–beneﬁt ratio of preoperative staging for
patientswithesophagealorgastriccancerisextremelylow.In
the ﬁnal analysis, biology always trumps staging, especially
for highlylethalcancersfor whichnomethodscurrentlyexist
to detect malignancies early in their natural history.
The controversy: is MIS an accepted approach
for curative treatment of esophageal cancer?
Pro: Three-ﬁeld radical open esophagogastrectomy is
the treatment of choice for esophageal cancer
Steven De Meester
Associate Professor in the Department of Cardiothoracic
Surgery at the University of Southern California
The ﬁrst report of an esophageal adenocarcinoma is
credited to White in 1898. A review of the literature in 1900
showed only six cases, and at the time, most physicians
believed these represented an extension of gastric tumors
into the distal esophagus. By the 1950s, scattered reports
describing adenocarcinoma developing within a columnar
lined esophagus began appearing, and the existence of a
primary esophageal adenocarcinoma was established.
Once a rare tumor, adenocarcinoma of the esophagus
currently is the cancer with the fastest rising incidence in
America. Recent data indicate that since 1975, the rate of
increase for adenocarcinoma of the esophagus in the Uni-
ted States has outpaced the next closest cancer, melanoma,
nearly threefold [99]. This previously uncommon tumor
now ranks within the top 15 cancers among U.S. white
males. Similar trends are reported in many European
countries, with the highest reported incidence (7 per
100,000) in the United Kingdom.
The tremendous increase in the incidence of esophageal
adenocarcinoma has led to a complete epidemiologic shift
such that in the United States and other industrialized
countries, adenocarcinoma has replaced squamous cell
carcinoma as the most common esophageal malignancy.
This year (2009), the United States will have approximately
13,000 new cases of esophageal adenocarcinoma [100].
To date, no therapy has proved superior to esophagec-
tomy for both the cure and palliation of patients with
localized esophageal cancer. The primary goal of surgery is
complete (R0) resection of the tumor and surrounding
lymph nodes to maximize the opportunity for cure and to
minimize the incidence of local recurrence. Findings have
conﬁrmed repeatedly that complete surgical resection is the
most important prerequisite for the long-term survival of
patients with localized esophageal cancer [101]. However,
accomplishing this goal is easier for intramucosal tumors
than for transmural tumors. Consequently, the surgical
approach and the extent of resection should be modiﬁed
based on the extent of disease present in each patient.
Currently, four main surgical options exist: vagal-spar-
ing esophagectomy without lymphadenectomy, en bloc
esophagectomy with thoracic and abdominal lymphade-
nectomy, transhiatal resection, and a minimally invasive
esophagectomy (laparoscopic procedure alone or a com-
bined thoracoscopic and laparoscopic approach). Although
few centers offer all four surgical options, each option
likely has a place for the appropriate patient, and each
offers potential advantages.
Vagal-sparing esophagectomy
The technique for a vagal-sparing esophagectomy was
described in the 1980s by Akiyama et al. [102] from Japan.
We have adopted this technique for patients with either
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of these patients, we have conﬁrmed vagal integrity. Vagal
preservation has led to a signiﬁcant reduction in the preva-
lence of dumping and diarrhea compared with standard
esophagectomy with vagotomy [103]. The vagal-sparing
procedure is applicable only for patients with intramucosal
tumors because no lymphadenectomy is performed. For
patients with a visible lesion, it is critical to conﬁrm that the
tumor is conﬁned to the mucosa because submucosal inva-
sion imparts a signiﬁcant risk of lymph node metastases and
precludes a vagal-sparing approach. Findings have demon-
strated that EUS, even with high-frequency 20-MHz probes,
cannot accurately distinguish mucosal from submucosal
invasion [86]. Consequently, we currently use endoscopic
mucosal resection (EMR) to stage the invasion depth of
small tumors (B1.5 cm) deﬁnitively and to determine the
appropriateness of a vagal-sparing esophagectomy [104].
En bloc esophagectomy
To deﬁne clearly what can be accomplished with surgery
alone for esophageal adenocarcinoma, we evaluated the
outcome after 100 consecutive en bloc esophagectomies.
Theoverallsurvivalratewas52%at5 years,and94%,80%,
77%, 24%, and 29%, respectively, for patients with The
AmericanJointCommitteeonCancerstages1,2a,2b,3,and
4 tumor [105]. During a detailed follow-up period (median,
40 months), 69% of the patients remained free of disease.
Systemic disease developed in 31% of the patients, but local
regional recurrence occurred for only one patient (1%).
Similarexcellentlocalcontrolandsurvivalrateswithenbloc
resection have been reported by Altorki and Skinner [106].
These data serve to refute the nihilistic attitude that
esophageal cancer is systemic and incurable at the time of
diagnosis. Moreover, the low incidence of local recurrence
after en bloc resection stands in stark contrast to the 20% to
40% incidence of local recurrence after transhiatal resec-
tion. Because local recurrence after esophagectomy typi-
cally results in rapid death from cancer, local control
remains a primary goal of therapy for this disease. Cur-
rently, en bloc resection is recommended for all patients
with limited nodal disease (B5 nodes on EUS) and good
cardiopulmonary status without signiﬁcant medical
comorbidities.
Transhiatal versus en bloc resection
Debate continues with regard to whether the approach and
extent of lymphadenectomy alter the survival in cases of
surgically treated esophageal adenocarcinoma. Increas-
ingly, evidence exists to show that it does. In a randomized
prospective trial, Omloo et al. [107] reported better sur-
vival for the group that had en bloc resection than for a
transhiatal group. However, the numbers were insufﬁcient
to reach statistical signiﬁcance.
In an analysis of the results for therapy of distal esoph-
ageal or gastroesophageal junction (GEJ) adenocarcinoma
in a well-deﬁned and stable Finnish population, Sihvo et al.
[108] found that patients who underwent en bloc resection
with two-ﬁeld lymphadenectomy had a signiﬁcantly better
survival rate than patients who had a less extensive resec-
tion. Interestingly, the 5-year survival rate after en bloc
resection was 50%, nearly identical to the 5-year survival
rate reported after en bloc resection in other series. Simi-
larly, the 5-year survival rate of 23% after non–en bloc
resection is similar to that reported in numerous series of
transhiatal resections with or without neoadjuvant therapy.
In an effort to compare the outcomes for en bloc and
transhiatal resection at our center, we carefully matched
patients with tumors of similar stage who underwent one or
the other procedure based on the presence or absence of
associated medical comorbidities. The study end point was
survival at 5 years, and all noncancer deaths were excluded
to eliminate concern regarding the different prevalences of
medical comorbidities in the groups. All the patients had
T3 N1 esophageal adenocarcinoma and a minimum of 20
lymph nodes resected and examined. A signiﬁcantly better
5-year survival rate was present for those who had en bloc
resection than for those who underwent transhiatal resec-
tion when more than one to eight nodes were involved.
However, with nine or more involved nodes, survival for
the two types of resection was similar [109]. This is
compelling evidence that the type of resection inﬂuences
survival for patients with limited regional disease because
all patients were followed a minimum of 5 years, and all
deaths were due to cancer.
Finally, for a difﬁcult group of patients (those with
residual disease after neoadjuvant chemoradiotherapy for
esophageal adenocarcinoma), we recently demonstrated
that survival after en bloc resection is signiﬁcantly
improved compared with transhiatal resection. The survival
rate was 29% at 3 years and 10% at 5 years after en bloc
resection compared, respectively, with 9% and 0% after
transhiatal resection [110]. Similar poor results with
transhiatal resection are reported by others. This has led to
the recommendation that surgery not be offered to patients
with residual disease after neoadjuvant chemoradiotherapy.
However, long-term cure occurred for some patients after
en bloc resection, supporting the importance of local con-
trol with this disease.
Minimally invasive esophagectomy
In the late 1990s, several centers began exploring the
potential for a minimally invasive esophagectomy (MIE).
Techniques have now been developed for both a
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esophagectomy. The disadvantages of a completely lapa-
roscopic approach include the inherent dangers of dissec-
tion near the pulmonary vessels high in the mediastinum
and the inability to accomplish a systematic thoracic
lymphadenectomy with this approach. However, the vagal-
sparing procedure is ideally suited to a laparoscopic
approach because the esophagus is stripped out of the
mediastinum without any dissection, and no lymphade-
nectomy is necessary for these patients with only high-
grade dysplasia or intramucosal cancer. For patients with
more advanced cancer, the combined thoracoscopic/
laparoscopic approach offers the advantage of a thoracic
lymphadenectomy and has been proved safe and effective
in a large series of patients.
Whether an MIE will offer such clear advantages in
hospital stay and recovery, with an outcome similar to that
for an open procedure, establishing it eventually as the
standard approach, similar to what happened with laparo-
scopic cholecystectomy and antireﬂux surgery, remains to
be determined. In particular, local recurrence rates after a
thoracoscopic/laparoscopic esophagectomy need to be
determined for an assessment of whether it provides the
advantages of complete resection together with the reduced
physiologic impact of a minimally invasive approach.
Postesophagectomy morbidity and quality of life
Esophagectomy with reconstruction is an enormous pro-
cedure associated with signiﬁcant postoperative morbidity
for many patients. Some of the most troubling early
symptoms, as reported by a patient who underwent
esophagectomy for cancer at the age of 40 years, are
nausea and gastric retention, dumping, diarrhea, and dys-
phagia related to anastomotic stricture. As a consequence
of these difﬁculties, as well as recovery from the discom-
fort of the operation and the slow process of regaining
stamina and energy, quality of life decreases signiﬁcantly
during the ﬁrst 6 weeks after esophagectomy and requires 6
to 9 months for a return to preoperative values. Findings
have shown quality of life to be similar after a transhiatal
or transthoracic resection.
Long-term functional outcome after esophagectomy was
reported by Headrick et al. [111] at the Mayo Clinic. At a
median of 5.3 years postoperatively, 7 (13%) of 48 patients
were entirely asymptomatic, 15% had dumping, 38% had
some degree of dysphagia, and 68% had gastroesophageal
reﬂux symptoms. Despite these difﬁculties, the patients’ 36-
Item Short-Form Health Survey quality-of-life scores were
better for the physical and emotional roles than the national
norm, although the health perception score was lower.
Social function scores improved with increasing time after
the operation but were adversely affected by the occurrence
of an anastomotic leak. Similar follow-up information,
together with data on quality of life after esophagectomy, is
becoming increasingly important because Barrett’s sur-
veillance programs are leading to the identiﬁcation of ear-
lier-stage tumors, which often are curable.
Consequently, surgeons need to place a major emphasis
on evaluating outcome and be willing to modify their
procedures to reduce the long-term morbidity of esopha-
geal resection and reconstruction for patients likely to live
for many years postoperatively. Efforts at vagal nerve
preservation, MIE, and reduction in incidence of anasto-
motic stricture and leak all are warranted to reduce mor-
bidity and improve quality of life after esophagectomy.
Route of reconstruction and choice of graft
In most circumstances, the posterior mediastinal route is
chosen for reconstruction. The posterior mediastinum,
typically a more direct and thus a shorter route for recon-
struction, has been shown to have a lower perioperative
morbidity rate, leading to better graft emptying than the
substernal route. If a substernal route is used, it is important
to recognize that the thoracic inlet can impair bolus pas-
sage into the graft. At our center, we routinely excise the
medial portions of the left clavicle and ﬁrst rib as well as
the left half of the manubrium to prevent this problem.
The most widely used esophageal replacement graft is
the tubularized stomach, with colon interposition or small
intestine grafts used less frequently as alternatives. Each
graft has advantages and disadvantages, but the familiarity,
reliable vascular supply, and single anastomosis required
with a gastric pull-up make it the ﬁrst choice for most
esophageal surgeons.
When the stomach is not available or for oncologic
reasons is unsuitable, a colon interposition based on the
ascending branch of the left colic artery is an excellent
option for reliable reconstruction. The requirement for
three anastomoses, the added time for mobilization, and the
potential for redundancy are clear disadvantages with colon
interposition, but it also has advantages including a reduced
incidence of anastomotic leak and stricture compared with
gastric pull-up.
Most esophagectomies involve division of the vagus
nerves, and thus a pyloroplasty typically is included with
the procedure. Although narrow gastric tubes can empty
satisfactorily without a pyloroplasty, some researchers
have found that the ischemia and anastomotic leak rates are
unacceptably high with narrow gastric tubes. Some centers,
particularly in Europe, omit a pyloroplasty and report no
signiﬁcant problems with delayed graft emptying or
regurgitation and aspiration events. However, a metaanal-
ysis concluded that pyloric drainage procedures reduce the
occurrence of early postoperative gastric outlet obstruction
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is beneﬁcial [112].
Currently, we use a simple and quick technique that
eliminates the risk of leakage. Through a gastrotomy along
the lesser curve in an area that will be excised with tubu-
larization of the stomach, we pass a 21-mm circular stapler
and excise a portion of the anterior pyloric channel. We
have used this technique for more than 2 years at our
institution, and it has been very effective.
Most esophageal surgeons anastomose the graft to the
cervical esophagus, and although the anastomotic leak rate
is higher with this technique, the consequences of a leak are
less signiﬁcant than a leak from an intrathoracic anasto-
mosis. The functional outcomes for high intrathoracic and
cervical anastomoses are similar, but the lower the anasto-
mosis, the greater the risk for signiﬁcant reﬂux, particularly
if it is placed below the level of the azygos vein.
Reﬂux of gastric juice occurs commonly after esopha-
gectomy and gastric pull-up because the lower esophageal
sphincter has been excised, and patients should be advised
to eat several hours before lying down at night and to sleep
with the head of the bed elevated. Despite these precau-
tions, it has been demonstrated that reﬂux-induced injury to
the esophageal squamous mucosa occurs proximal to the
anastomosis, and 50% of patients have been found to have
cardiac columnar metaplasia proximal to the anastomosis,
as shown by postoperative endoscopy [113, 114]. Of con-
cern, goblet cells indicative of recurrent Barrett’s esopha-
gus can be found in as many as one-half of these patients.
Neoadjuvant chemoradiotherapy
Three of the drugs most commonly used to treat esophageal
cancer (cisplatin, 5- ﬂuorouracil [5-FU], and mitomycin)
also enhance radiation effects. To take advantage of these
radiosensitizing beneﬁts, a number of clinical trials have
been conducted in which radiation and chemotherapy were
given before resection. To date, seven randomized pro-
spective trials have been reported (one only in abstract
form), and only the trial by Walsh et al. [115] found a
survival beneﬁt with neoadjuvant chemoradiotherapy. The
other six trials, including the ﬁnal analysis of the Univer-
sity of Michigan (Urba) trial, found that neoadjuvant che-
moradiotherapy offered no survival beneﬁt over surgery
alone [116].
Since publication of the Walsh trial, a number of con-
cerns have been raised that call into question the reliability
of the results. Much of the concern has focused on three
issues: substandard systemic staging because CT scanning
was not routinely used; the large number of withdrawals
from the protocol and the rationale for them, particularly in
the multimodal group; and the inclusion of patients who
underwent substandard surgical resections. However, the
greatest concern is that the statistical analysis appears to be
ﬂawed.
Careful review of the data in the text of the manuscript
and the Kaplan–Meier survival curves demonstrate that the
median and the 1-, 2-, and 3-year survival data presented in
the paper for the multimodal group do not correspond with
the survival curve for this group, whereas the curve for the
surgery alone group matches appropriately.
In response to this criticism, an erratum has been pub-
lished suggesting that the ﬁgures were mislabeled. How-
ever, even this does not correct the problem, and personal
requests to the New England Journal of Medicine for
independent statistical review of all the data have been
denied. All in all, the trial falls short of providing con-
clusive evidence for the superiority of neoadjuvant che-
moradiotherapy before surgery in the treatment of
esophageal cancer.
In an attempt to clarify the role of neoadjuvant therapy
for esophageal cancer, Fiorica et al. [117] performed a
metaanalysis of the published randomized trials. These
authors concluded that the pooled estimate of the treatment
effect was statistically signiﬁcant in favor of neoadjuvant
chemoradiotherapy followed by surgery for overall sur-
vival. However, these authors conceded that exclusion of
the Walsh trial led to a loss of statistical signiﬁcance
between groups. Given the problems with the Walsh trial,
as outlined earlier, it must be concluded that the meta-
analysis does not demonstrate better survival with neoad-
juvant therapy than with surgery alone for esophageal
cancer.
Neoadjuvant chemoradiotherapy followed by surgery:
critical appraisal
A review of the trials allows several comparisons to be
made and a few conclusions to be reached. At the outset, is
important to recognize that all the trials suffer from a rel-
atively low power to detect small differences between
groups given the small sample size in each trial. Further-
more, variations in the chemotherapy and radiation proto-
cols also confound attempts at a metaanalysis. Despite
these issues, it is interesting to note that the 3-year survival
rate in the multimodal groups was similar to those in the
Walsh (32%) and Urba (30%) trials. However, there was a
substantial difference in 3-year survival for the surgery
alone groups (6% vs. 16%, respectively). Consequently, the
different outcomes in the Walsh and Urba trials were lar-
gely a consequence of the difference in survival in the
surgery alone groups.
The 3-year survival rate of 6% in the Walsh trial is less
than half the average survival rate for surgery alone in the
other ﬁve randomized studies (17%). Indeed, it is one of
the worst surgical survivals ever reported for this disease.
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adequate systemic staging and the substandard surgical
resections in that trial.
A second conclusion is that neoadjuvant chemoradio-
therapy did not reduce the incidence of systemic recur-
rence. This is consistent with reports that neoadjuvant
chemoradiotherapy does not reduce the prevalence of bone
marrow micrometastases.
Instead, the major impact of neoadjuvant chemoradio-
therapy appears to be better locoregional disease control, in
effect compensating for inadequate surgical resections.
These trials demonstrate two clear messages: To have an
impact on survival for patients with locally advanced
esophageal cancer, surgeons need to minimize the inci-
dence of local recurrence by performing an adequate
resection, and oncologists need to reduce the incidence of
systemic failure with more efﬁcacious chemotherapy.
It is proposed that improved local control may be
obtained with higher doses of preoperative radiation.
However, even the high doses of radiation used for deﬁn-
itive treatment of esophageal cancer do not reliably elim-
inate local-regional disease. In addition, the rates of
infection, anastomotic breakdown, adult respiratory dis-
tress syndrome, long-term respirator use, and mortality all
are greater for patients receiving neoadjuvant chemora-
diotherapy with radiation in large doses ([45 Gy) or with
high fractionation schedules ([200 cGy/day).
A last conclusion from the trials is that if neoadjuvant
chemoradiotherapy offers one glimmer of hope, it is that
approximately 20% of patients who had a complete path-
ologic response demonstrated excellent survival (64%)
compared with those who had residual disease in the
resected specimen (19%) at 3 years in the Urba trial. A
note of caution, however, is that only the clinical stage of
the disease was known for these patients before therapy.
Wang et al. [118] have demonstrated with minimally
invasive pathologic staging that only patients without
lymph node metastases were likely to have a signiﬁcant
treatment response. Obviously, patients with limited dis-
ease, especially those with N0 tumor, also are those who do
well with resection alone. It is the patients with extensive
disease and multiple involved lymph nodes who are most
in need of an improved survival with neoadjuvant therapy,
and unfortunately, it appears that these are the very patients
least likely to achieve a complete pathologic response.
Furthermore, there is increasing evidence that patients
who fail to achieve a complete pathologic response not
only derive no beneﬁt from the neoadjuvant therapy, but in
fact may have a worse survival rate than those who
undergo resection alone. This concern was conﬁrmed in a
recent publication from the Cleveland Clinic emphasizing
the better survival for patients who had T2N0 tumors
treated with primary surgical resection than for patients
who underwent neoadjuvant therapy [119]. Therefore, in
my opinion, until complete pathologic response rates
improve or we are able to identify accurately those patients
most likely to achieve a complete response, a generic
recommendation of neoadjuvant chemoradiotherapy for
patients with esophageal adenocarcinoma is unwarranted.
Palliation for esophageal carcinoma
Surgical resection with esophageal replacement using the
stomach or colon remains the standard for both curative
treatment and palliation of patients with esophageal cancer.
However, for patients with systemic metastases or unre-
sectable local disease, esophageal bypass procedures are
associated with high mortality and short postoperative
survival rates, and with rare exceptions, are no longer per-
formed. Instead, palliation for these patients is best obtained
with the use of coated, self-expanding metal stents.
Advancements in technology have revolutionized both the
ease of placement and the safety of esophageal stents. As a
consequence, few indications remain for the use of photo-
dynamic therapy (PDT) or laser with these patients [120].
New horizons in the treatment of esophageal cancer
Signiﬁcant strides continue to be made in the treatment of
patients with cancer. One area certain to play an increas-
ingly important role is chemosensitivity testing. A better
understanding concerning the molecular impact of chemo-
therapeutic agents and new methods for rapid, reliable, and
less labor-intensive analysis of the genes involved have
opened the door for testing responsiveness to a steadily
expanding list of chemotherapy agents. Other treatment
strategies that may play a role include the use of angio-
genesis inhibitors and the use of immunotherapy. However,
early detection while the tumor still is intramucosal offers
the surest way to cure esophageal cancer. Thus, surveillance
endoscopy for patients with Barrett’s esophagus and per-
haps endoscopic screening of high-risk patients with long-
standing reﬂux may be the most helpful strategy currently.
Con: Total MIS esophagectomy is the treatment of
choice for esophageal cancer
James D. Luketich
Chief of the Heart, Lung and Esophageal Surgery
Institute at the University of Pittsburgh Medical Center
Arjun Pennathur
Since the initial description of laparoscopic fundopli-
cation in 1991 [121], esophageal surgeons have increas-
ingly incorporated the techniques of MIS into their
practice. This is supported by several surgical series that
have documented the beneﬁts of MIS for the treatment of
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[125–127]. A consistent ﬁnding of these reports is the
equivalent efﬁcacy and decreased recovery times of lapa-
roscopic surgery compared with traditional open surgery.
These reports have led to increasing surgical referrals for
the management of these diseases, although alternative
medical therapies are available [128].
Minimally invasive surgery offers several potential
beneﬁts for patients with esophageal cancer. Esophagec-
tomy is associated with signiﬁcant morbidity and mortality
rates [129, 130]. The risks associated with open esopha-
gectomy have led to increasing interest among oncologists
for treating patients with deﬁnitive chemoradiation alone
[131, 132]. Unfortunately, some of these data have been
extrapolated to healthy patients with high-grade dysplasia
or early-stage esophageal cancer in whom very high 5-year
survival rates can be anticipated after esophagectomy. It is
critical for surgeons to reﬁne the esophagectomy technique
and to reduce the risks associated with it.
In an effort to reduce the risks of esophagectomy, we
have adopted a minimally invasive approach to the pro-
cedure [133]. Currently, MIE is being adopted in many
centers. This approach has several potential beneﬁts.
In this report, we summarize the technique and results of
MIE and the studies that have compared a minimally
invasive approach to an open approach for esophagectomy.
MIE technique
The technique for MIE has evolved as our experience with
other minimally invasive foregut procedures, such as lap-
aroscopic Heller myotomy, repair of giant paraesophageal
hernias, and staging for esophageal cancer, has grown. To
date, we have performed more than 500 MIEs at the Uni-
versity of Pittsburgh Medical Center.
InitialattemptsatMIEwerehybridoperationscombining
traditional open surgery with minimally invasive tech-
niques. The ﬁrst such report by Collard et al. [134] in 1993
included 12 patients who underwent thoracoscopic mobili-
zation of the esophagus followed by laparotomy and prep-
aration of the gastric conduit. In that series, two patients
required conversion to thoracotomy because of bleeding.
Several subsequent reports have demonstrated the feasibil-
ity of this approach. However, no deﬁnitive beneﬁt has been
shown compared with open esophagectomy [135, 136].
A completely laparoscopic transhiatal esophagectomy
also has been described. The largest series, published by
DePaula et al. [137] in 1995, described 48 patients who
required esophagectomy predominantly for end-stage
achalasia secondary to Chagas’ disease. Only two patients
required conversion to laparotomy.
TheﬁrstexperiencewithMIEintheUnitedStateswasnot
reported until 1997, when Swanstrom and Hansen [138]
described a carefully selected group of nine patients with




MIE at the University of Pittsburgh
Similar to these early reports, our initial efforts at MIE
were through the transhiatal approach. However, although
this simpliﬁes patient positioning and does not require
single-lung ventilation, we found that the disadvantages
were signiﬁcant. The small working space through the
hiatus allowed limited access to the middle and upper third
of the esophagus and made any thoracic lymph node dis-
section extremely difﬁcult. Because of this, our current
approach includes a right VATS to mobilize the thoracic
esophagus followed by laparoscopy to prepare the gastric
tube. Patients found to have bulky nodal metastases by CT
scan or staging laparoscopy are not thought to be candi-
dates for MIE, and consideration is given to either an open
operation or deﬁnitive chemoradiation.
We have described our technique in detail and published
our results for 222 consecutive patients who have under-
gone MIE at the University of Pittsburgh [92]. Esopha-
gectomy was performed with thoracoscopy, laparoscopy,
and cervical anastomosis. Although early in the series we
selectively performed MIE for patients with smaller tumors
and no previous therapy, 35% of the patients in this series
had been treated with chemotherapy and 16% with radia-
tion. In addition, 25% of the patients had undergone prior
open abdominal surgery. For 206 of the patients (93%),
MIE could be completed as planned. No emergent con-
versions to an open procedure were necessary for bleeding.
The operative mortality rate was 1.4%. This very low
mortality rate compares favorably with that for the largest
series of open esophagectomy (Table 1). The rate of anas-
tomotic leak in this series was 11.7%. The median intensive
care unit (ICU) stay was 1 day, and the hospital stay was
7 days. The survival rate was comparable with that in open
series. In addition, the quality of life was well preserved.
We also have reported our results after minimally
invasive Ivor Lewis esophagectomy for 50 patients at the
University of Pittsburgh [139]. This is a good option,
especially for patients with extensive involvement of the
cardia in whom the conduit may not reach to the neck.
Prone positioning
Another modiﬁcation of the thoracoscopic approach is
positioning of the patient in a prone position [140]. The
potential advantage of this technique is that the lung and
blood do not obscure the view of the esophagus. In fact,
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because the ipsilateral lung will fall away from the ﬁeld
due to gravity.
The largest reported experience with prone positioning
is described by Palanivelu et al. [141] from India. All 130
patients in this series had squamous cell cancer of the
midthoracic esophagus, and only one patient received
neoadjuvant therapy.
With prone positioning, the esophagus is ﬁrst mobilized
thoracoscopically using three ports with the patient in the
prone position. The patient then is turned to the lithotomy
position, and mobilization of the esophageal hiatus and
stomach is performed laparoscopically. A minilaparotomy
then is performed for tumor extraction, creation of the
gastric tube, and pyloroplasty. The procedure is concluded
with a cervical anastomosis.
Early results after this procedure are encouraging. The
median ICU stay was 1 day, and the overall mortality rate
was 1.5%. The major morbidity rate was 11%, and the
anastomotic leak rate was only 3%. Stage-speciﬁc survival
after this procedure was equivalent to that of open series.
These results of low morbidity and mortality rates favor a
minimally invasive approach.
Comparison of MIE with open esophagectomy
For optimal outcomes, MIE techniques require advanced
laparoscopic and thoracoscopic skills. For this reason and
due to the inherent constraints of visualization and instru-
mentation, the operative times for MIE are longer and
encompass a wide range (3.7–7.5 h) (Table 1). Most open
esophagectomies can be performed within 3 to 6 h.
Although the time required for MIE is longer, we believe
that the minimally invasive approach translates into a lower
incidence of postoperative pain, fewer pulmonary compli-
cations, and a shorter hospital stay. However, to date, no
randomized studies have compared outcomes between
open esophagectomy and MIE. Nevertheless, a few pub-
lished single-institution series have compared a minimally
invasive approach with historical controls.
Table 1 Comparison of minimally invasive and open esophagectomy series
Year n Approach OR (AQ39) LOS (days) Mortality (%)
Total MIE
DePaula [137] 1995 12 Lap THE 4.3 7.6 0
Swanstrom and Hansen [138] 1997 9 Lap THE 6.5 6.4 0
Watson et al. [44, 154] 2000 7 MIE 4.4 12 0
Luketich [82, 125, 133] 2003 22 MIE NR 7 1.4
Nguyen [61, 142, 143] 2003 46 MIE 5.8 8 4.3
Hybrid
Gossot [155] 1995 29 VATS/laparotomy 2.3
a NR 3.8
Jagot [156] 1995 9 Lap-assisted 8.5 10.3 0
Liu [157] 1995 20 VATS/laparotomy 4.6
a 19 0
Peracchia [158] 1997 18 VATS/laparotomy 5.6 NR 5.5
Law [159] 1997 18 VATS/laparotomy 4 NR 0
Kawahara [160] 1999 23 VATS/laparotomy 1.8
a 26 0
Smithers [144, 161] 2001 15 VATS/laparotomy 5.0 12 3.3
Osugi [147] 2003 80 VATS/laparotomy 3.7 NR 0
Open
Mathisen [162] 1988 10 TS (64)/IL (40) NR NR 2.9
Lerut [163] 1992 19 Open (varied) NR 18 9.6
Orringer [164] 1999 10 THE NR 7
b 4
Swanson [165] 2001 25 Three-hole NR 13 3.6
Bailey [166] 2003 17 Open (varied) NR NR 9.8
Rizk [167] 2004 51 Open (varied) NR 23
c 6.1
OR operating room; LOS length of hospital stay; Lap laparoscopic; THE transhiatal esophagectomy; MIE minimally invasive esophagectomy;
VATS video-assisted thoracic surgery; NR non-reportable; TS thoracoabdominal; IL Ivor-Lewis
a VATS portion only
b In last two years of series
c Pts. with complications
Reprinted from Kent et al. [191]
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and open (n = 16) esophagectomy, Nguyen et al. [142, 143]
found that the mean operative time (364 min), blood loss
(297 ml), and length of ICU stay (6.1 days) were less than
with open transthoracic esophagectomy (437 min,
1046 ml, and 9.9 days, respectively) or blunt transhiatal
esophagectomy (391 min, 1142 ml, and 11.1 days,
respectively). The incidence of respiratory complications
(pneumonia, pulmonary embolism, respiratory failure) was
similar between the groups.
It should be emphasized that the groups in this retro-
spective comparison had signiﬁcant differences. The open
patients had more advanced cancers and were treated by a
group of four surgeons with variable experience, whereas
the MIE procedures were performed by a single surgeon
with expertise in minimally invasive esophageal surgery.
The open operations were performed several years before
the MIE procedures, so differences in practice may account
for the longer hospital stays.
Another study that evaluated the beneﬁts of MIE was
reported by Narumiya et al. [144]. In this study, 40 patients
who underwent esophagectomy were prospectively ran-
domized to either a conventional open approach or a
‘‘mini’’ thoracotomy and ‘‘mini’’ laparotomy. The patients
who had the more limited incisions were noted to have
signiﬁcantly fewer narcotic requirements and a shorter
hospital stay. It is reasonable to assume that the beneﬁts
would be even more signiﬁcant had the patients undergone
a true MIE rather than a less extended open operation.
In a more recent study, Smithers et al. [145] reported the
outcomes for a total of 446 patients who underwent
esophagectomy. The approaches used for these patients
were open (thoracotomy and laparotomy for 114 patients),
thoracoscopically assisted (thoracoscopy and laparotomy
for 309 patients), and total MIE (thoracoscopic and lapa-
roscopic procedure for 23 patients). The minimally invasive
group experienced less blood loss and a shorter hospital
stay. They also had higher stricture rates. No signiﬁcant
differences in the lymph node retrieval or survival were
noted when the groups were compared stage for stage.
In another study, Braghetto et al. [146] reported the
results for a total of 166 patients, of whom 60 underwent
transthoracic esophagectomy, 59 underwent transhiatal
esophagectomy, and 47 underwent MIE. The early and late
complication rates were signiﬁcantly decreased in the MIE
group.
Osugi et al. [147] compared 72 patients who underwent
esophagectomy using three-ﬁeld lymphadenectomy and the
standard posterolateral thoracotomy with 77 patients who
underwent the procedure using a thoracoscopic (VATS)
assisted approach with a minithoracotomy. The mean
number of lymph nodes removed, the blood losses, and the
morbidity rates were similar. The decrease in vital capacity
was less in the VATS group. The survival rates were
similar.
In summary, a review of these studies comparing a
minimally invasive approach to an open approach shows
favorable results with regard to a minimally invasive
approach.
Survival and quality of life after MIE
The other issue in assessing the beneﬁts of MIE is the
quality of life after surgery. There are limited data on
quality of life after esophagectomy. In an interesting study,
Taguchi et al. [148] evaluated the impact of the approach to
esophagectomy on pulmonary function tests, exercise tol-
erance, and quality of life for 51 patients. These authors
compared the outcomes of patients who underwent a
standard posterolateral thoracotomy versus thoracoscopic
approach. All the patients had a laparotomy and a cervical
anastomosis. The thoracotomy group had less decline in
vital capacity, and dyspnea-limiting exercise tolerance was
more common. The maximum oxygen uptake was similar
in the two groups. No differences in survival were noted
between the groups.
In our series, the quality of life was evaluated by
administering validated quality-of-life and disease-speciﬁc
questionnaires to patients who had undergone MIE. Over-
all, both the postoperative dysphagia and heartburn scores
were excellent, and only 4% of the patients questioned had
signiﬁcant reﬂux. Also, the overall quality of life as mea-
sured by the Short-Form 36 was no different from that of
age-matched control subjects. In summary, the quality of
life appears to be well preserved after MIE.
New developments in MIE
Robotic MIE Another modiﬁcation to MIE is the use of
robotic assistance. Early attempts restricted the use of the
robot to the thoracic mobilization. Although the operative
time was lengthy, the robot was thought to eliminate some
of the ergonomic difﬁculties with standard thoracoscopy,
and in addition could provide the surgeon with a true three-
dimensional ﬁeld of view [149, 150]. Subsequently, entirely
robotic esophagectomies have been performed, using both
Ivor Lewis [151] and transhiatal approaches [152].
The advantages of the robot are likely to be most sig-
niﬁcant with the transhiatal approach. The working space
through the hiatus is quite small, and dissection becomes
increasingly difﬁcult as it is carried toward the carina. This
difﬁculty led us to abandon, in part, the laparoscopic
transhiatal esophagectomy in favor of a three-hole tech-
nique. These difﬁculties are decreased with the graded
motion and several degrees of rotational freedom used in
the robotic system.
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reports or small series. The largest series, published only as
an abstract, reported on nine patients who underwent a
totally robotic transhiatal esophagectomy [153]. In that
report, the mean operative time was 5 h, and the average
length of hospital stay was 8 days. This study and others
demonstrate the technical feasibility of robotically assisted
esophagectomy. An appreciation for the beneﬁts of the
robot, if any, will not be possible until experience with the
technique increases signiﬁcantly.
Conclusions
Minimally invasive esophagectomy can be performed with
acceptable morbidity, low mortality, and oncologic results
potentially equivalent to those for the open approach. A
multi-institution trial is underway to document the poten-
tial advantages of MIE. This trial is sponsored by the
Eastern Cooperative Oncology Group (ECOG 2202), with
the participation of multiple centers across the United
States and with the University of Pittsburgh serving as the
coordinating center. The completion of this study hopefully
will demonstrate the beneﬁts of the procedure and docu-
ment that its advantages can be realized at other centers
(Table 1 [133, 137, 138, 142, 147, 153–167]).
The controversy: do all patients with curable gastric
cancer require radical open resection?
Pro: Open regional D2 lymphadenectomy is the
standard of care for all patients with curable gastric
carcinoma
Martin Karpeh
Chief of Surgical Oncology at the State University of
New York–Stony Brook
In the West, the incidence of adenocarcinoma
involving the stomach has diminished signiﬁcantly over
the past century. In the United States, gastric cancer
dropped from being the most common cause of cancer
death in the 1940s to the current rank of 14th. In 2007,
the American cancer society data reported 21,260 new
cases of stomach cancer and 11,210 deaths, compared
with 112,340 cases of colon cancer. The change in
cancer incidence, coupled with the precipitous drop in the
number of operations for benign ulcers, has had a major
impact on the number of stomach operations performed
by most surgical residents.
Obtaining a complete surgical resection is an essential
component in the curative treatment of this disease.
Moreover, understanding the natural history of gastric
cancer and its patterns of progression is critical to
achieving an R0 resection [168]. This understanding has
evolved considerably in the past decade [169]. The concept
that all gastric cancers require a radical en bloc total gas-
trectomy has been modiﬁed to reﬂect both tumor and
patient characteristics. Tumor size, depth of invasion, and
extent of lymph node involvement now clearly determine
the extent of surgery needed to achieve an R0 resection.
The extent of lymph node dissection needed for cure has
been a point of controversy in gastric cancer surgery for
decades. The rationale for performing a D2 lymphade-
nectomy is to increase the probability of clearing local
regional lymph nodes at risk for clinical and occult
metastases. In an analysis of 100 consecutive T1-3 N0 and
T1-3 N1 gastric cancers, Siewert et al. [170] demonstrated
a high frequency of micrometastases in clinically negative
nodes. In this multivariate analysis, the presence of mi-
crometastases was independently associated with a worse
prognosis. Their results suggest that the D2 lymphade-
nectomy was advantageous for patients with either lymph
node metastases to perigastic level 1 nodes or node-nega-
tive trans-serosal tumors (pT3), for whom the risk of
missing micrometastases would be greatest.
According to the guidelines of the Japanese Research
Society for Gastric Cancer, the D1 dissection (formerly R1)
involves the removal of perigastric (level 1) nodes located
directly along the lesser and greater curvatures of the
stomach (stations 1–6). An incomplete level 1 dissection is
labeled a D0 lymphadenectomy. The D2 lymphadenectomy
removes the aforementioned perigastic nodes (stations 1–
6), the nodes along the left gastric artery (station 7), the
common hepatic artery (station 8), the celiac trunk (station
9), the splenic hilum and the splenic artery (stations 10 and
11). The ‘‘classic’’ D2 lymphadenectomy included a distal
pancreatectomy and splenectomy to resect stations 10 and
11. Currently, the pancreas and spleen are rarely resected
when a D2 lymphadenectomy is performed in the absence
of direct tumor invasion [171, 172].
With the aforementioned background, a number of
prospective randomized trials have attempted to evaluate
the effect of performing the larger D2 lymphadenectomy
compared with a standard D1 (Table 1). To date, no sur-
vival advantage has been demonstrated for the D2 proce-
dure, but increased morbidity and mortality have been
attributed to the larger lymphadenectomy. Hartgrink et al.
[173] evaluated the 11-year follow-up study of the patient
entered into the largest lymphadenectomy trial published to
date. In a subset analysis by N stage, the authors found no
beneﬁt of the D2 lymphadenectomy for N0 or N1 patients
(1 to 6 positive nodes). Patients with 7 to 15 positive nodes
had a better survival after the D2 node dissection than after
the standard D1. These authors concluded that an extended
lymph node dissection may offer a cure for patients with
N2 disease, but cautioned that extended lymph node
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123dissections may not be of beneﬁt if morbidity and mortality
can be avoided.
We have the ability to identify which gastric cancer
patients are likely to beneﬁt from the more extended D2
lymphadenectomy based on their T-stage and to a lesser
extent on tumor size. In evaluating the T- and N-stage of
the 711 patients entered into the Dutch trial, it is not sur-
prising that the trial was negative with regard to survival.
In this trial, 75% of the patients had either a T1 or T2
tumor, and nearly 50% were node negative [173, 174].
Such a patient population is not likely to have a high
metastatic lymph node burden.
We know that properly staged node-negative T2a and
T2b tumors do very well after resection [175], making it
even more difﬁcult to show a survival difference. In con-
trast, nearly 80% of patients with T3 tumors will be node
positive, and 40% will have seven or more positive nodes
(N2 disease), as shown by routine hematoxylin and eosin
staining. These patients do very poorly and were under-
represented in the Dutch trial. For studying the impact of
an extended lymphadenectomy, T3 patients would have
been the appropriate population. With these data in mind,
the subset analysis becomes even more relevant.
The opposite situation was observed in the U.S. trial of
postoperative chemoradiation for gastric cancer, which
randomized patients to observation or postoperative che-
moradiation after a curative gastrectomy for gastric cancer
[176]. An analysis of the tumor characteristics of the
patients treated in that trial showed that 85% had T3 and
node-positive tumors, yet the extent of lymphadenectomy
was D2 for only 10% and D1 for 36%, with 54% having
what was described as a D0 resection. Hundahl et al. [177]
further analyzed these data and found that undertreatment,
as deﬁned by a high Maruyama index, was associated with
the D1 and D0 lymphadenectomy as well as poor survival
independent of the adjuvant treatment received.
The lesson learned from these to trials is that the treat-
ment should match the disease such that patients with
advanced T3 tumors, who are at risk of having extensive
nodal disease, may beneﬁt from a more extensive node
dissection provided it is performed safely. On the contrary,
more early-stage disease (T1 or T2a) can be treated with a
standard D1 node dissection or less depending on the
characteristics of the tumor [178].
Higher morbidity and mortality rates have been associ-
ated with the D2 lymphadenectomy than with the standard
D1 [119, 179–181]. Both the British and Dutch trials found
that the practice of routine distal pancreatectomy and
splenectomy signiﬁcantly increased postoperative morbid-
ity and mortality [119, 127]. A proper D2 can be performed
without the need for distal pancreatectomy or splenectomy.
A recent prospective randomized trail of D1 versus D2
lymphadenectomy avoiding pancreaticosplenectomy
demonstrated no increase in morbidity or mortality in a
multicenter series of well-trained Italian surgeons [182].
Another randomized trial of D2 versus D2 plus paraaortic
nodal dissection also showed a very low morbidity and
mortality rate [183]. Both trials involved specialty centers
and surgeons quite familiar with performing D2 lym-
phadenectomy, suggesting that experience matters.
Applying laparoscopic techniques to perform a D2
lymphadenectomy introduces another layer of complexity
that will require study for an understanding of what, if any,
beneﬁt it confers. Preliminary data suggest that a laparo-
scopic distal gastrectomy can be performed safely, but the
numbers are too small to provide meaningful data [184].
Additional beneﬁts of laparoscopic gastrectomy were
reduced blood loss, shorter time until resumption of eating,
and shortened hospital stay. However, only 20 open and 21
laparoscopic lymphadenectomy procedures were per-
formed in the study.
The incidence of gastric cancer continues to decrease in
the United States and the Western world, suggesting that the
disease is being diagnosed at an earlier stage. The oppor-
tunities to gain sufﬁcient experience performing a safe open
D2 lymphadenectomy are becoming less frequent. This
issue is even greater whenit comes to learning how to do the
operation laparoscopically. The results of adjuvant treat-
ment for gastric cancer suggest that surgery still is the
essential component if cure is to be achieved. Without a
sufﬁcient volume of cases, my concern is that laparoscopy
will not be put to the proper tests for the answers we need
before we introduce it into standard practice.
Con: MIS approaches (endomucosal resection,
laparoscopic gastrectomy, and sentinel node)
are appropriate for selected patients with curable
gastric cancer
Ichiro Uyama
Department of Surgery at the Fujita Health University
School of Medicine
Endoscopic mucosal resection has been established as
an advanced ﬁrst-choice treatment for early gastric cancer
without lymph node metastasis. When lymph node
metastases are present, it is controversial whether laparo-
scopic surgery should be performed as treatment. Although
the extent of lymphadenectomy is being debated in other
parts of the world, Japan has suggested D2 lymph node
dissection as the standard of care for carcinomas with
lymph node metastasis since the 13th edition of the Japa-
nese Classiﬁcation of Gastric Carcinoma (JCGC) was
published in June 1999 [185]. According to the latest edi-
tion of the JCGC, curable gastric cancers with lymph node
metastasis should be treated with laparoscopic D2 dissec-
tion. However, some practitioners have yet to acquaint
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study describes the techniques used and the initial results
for laparoscopic D2 dissection (according to the latest
edition of the JCGC) used to treat gastric cancer.
Selection of patients
EMR Endoscopic mucosal resection is indicated for
patients with well- or moderately differentiated mucosal
cancer, that is, tumors smaller than 2 cm in diameter with
no lymph node metastasis [186].
Laparoscopic gastrectomy with lymph node dissec-
tion The indications for laparoscopic surgery to treat
gastric cancer in our study included contraindications to
EMR, depth of tumor invasion (i.e., tumor conﬁned to the
subserosal layer [cT2]), and no evidence of lymph node
metastasis or metastasis conﬁned to group 3nodes (less than
cN2). Bulky tumor was a contraindication. Neither tumor
location nor histologic type was considered in the selection
criteria. Patients with medical conditions that precluded
general anesthesia were not enrolled in this study.
Operating room setup
All procedures were performed with the patients under
general anesthesia and in the supine position with their legs
apart. A head-up tilt (208) was used to prevent the trans-
verse colon or small intestine from visually compromising
the operative ﬁeld. The primary surgeon stood to the
patient’s right, with the ﬁrst assistant on the patient’s left
and the camera operator between the legs. A video monitor
was placed over the patient’s head.
Surgical technique
A pneumoperitoneum was established using the open
technique, and six ports were placed as shown in Fig. 1.
The ﬂexible laparoscope (Olympus Corporation, Tokyo,
Japan) was introduced through the infraumbilical port.
Distal gastrectomy [187, 188]
Lymph node dissection and gastric resection: The gas-
trocolic ligament including the lymph node station no. 4sb
lymph nodes was divided proximally about 3 cm from the
left epiploic arcade toward the lower pole of the spleen
using laparosonic coagulating shears (LCS) or a vessel-
sealing system (LigaSure). The left gastroepiploic vessels
were exposed using the dissector and divided with clips.
The lymph node station no. 4sb lymph nodes were divided
from the greater curvature using the LCS or LigaSure.
After division of the gastrocolic ligament, including
lymph node station no. 4d, distally toward the pylorus,
attention was directed toward the inferior edge of the
pancreas. In focusing on this region, the middle colic vein,
superior mesenteric vein, gastrocolic trunk, and right gas-
troepiploic vein were exposed, and lymph node station
no.14v was dissected using the LCS. The roots of the right
gastroepiploic vessels were divided with clips, and lymph
node station no.6 lymph nodes were dissected from the
duodenum using the LCS (Fig. 2).
The duodenum was transected 1 cm distal to the pylorus
using an endoscopic stapling device as a prelude to division
of the right gastric vessels. Next, the proper hepatic artery
was skeletonized using the LCS. This procedure allowed
the dissection of lymph node station no.12a and identiﬁ-
cation of the root of the right gastric artery, which was
subsequently divided by clipping.
After the dissection of lymph node station nos.12a and
5, tape, which encircled the common hepatic artery, was
Fig. 1 Placement of ports
Fig. 2 Complete dissection of #6 and 14v lymph nodes. RGEA, right
gastroepiploic artery; RGEV, right gastroepiploic vein; SMV, supe-
rior mesenteric vein
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123retracted caudally. After the retraction, the common
hepatic artery was skeletonized, and lymph node station no.
8a was dissected using the LCS. Next, the root of the
splenic artery was isolated and taped with the vessel tape.
The proximal splenic artery was skeletonized along the
upper border of the pancreas, and lymph node station no.
11p was dissected using the LCS. The left gastric vein was
divided, and the root of the left gastric artery was exposed
and divided with double clips, allowing dissection of the
lymph node station no.7 lymph nodes. Further dissection of
the lymph node station no.9 lymph nodes was added
proximally. The lymph node station nos.1 and 3 lymph
nodes were dissected together with skeletonization of the
upper third of the lesser curvature.
After creation of the minilaparotomy (length, 4–5 cm)
on the upper abdomen, the stomach was transected via this
minilaparotomy extracorporeally, and an en bloc resection
of the stomach and D2 lymph nodes was completed. The
complete lymph node dissection is shown in Fig. 3.
Reconstruction: In the reconstruction, the intracorporeal
anastomosis was performed with a Roux-en-Y gastrojeju-
nostomy using linear staplers.
Total gastrectomy [189, 190]
Lymph node dissection and gastric resection: Under
laparoscopic vision, the body and tail of the pancreas and
spleen were mobilized from the retroperitoneal space. After
ligation and division of the splenic vein and artery with the
vascular stapler, splenectomy was performed to remove the
lymph node station no. 10 lymph nodes. Next, the mobi-
lized pancreas was retracted caudally, and the lymph node
station no. 11d lymph nodes were dissected (Fig. 4).
Finally, the lymph node station nos. 6, 5, 12a, 8a, 9, 7, and
11p lymph node dissections were performed as described
earlier for distal gastrectomy.
Reconstruction: An intracorporeal esophagojejunostomy
was created using the linear stapler, as shown in Fig. 5, and
the R-Y limb jejunojejunostomy was made extracorpore-
ally via minilaparotomy.
Results
From July 1999 to December 2006, we performed laparo-
scopic gastrectomies with lymph node dissection for 462
patients who had gastric cancer. In this series, 120 cases
were managed laparoscopically with standard lymph node
dissection (D2), and 330 were managed with limited type
dissection. There were no mortalities, and postoperative
recovery was uneventful.
The average operative time was 284 min (range, 212–
458 min), which was signiﬁcantly longer than for the
corresponding open surgery. The average blood loss was
76 g (range, 10–386 g), and blood transfusion was not
required for all the patients. The average number of lymph
nodes harvested per patient using the D2 resection was 58.4
(range, 37–104). As determined by unpaired Student’s t-
test, this number was signiﬁcantly different from the
number of nodes harvested (average, 42.8) in the laparo-
scopically limited type lymph node dissection (n = 330), as
we reported previously. Moreover, there was no statistical
difference between the laparoscopic and conventional open
D2 dissections in terms of the number of nodes harvested
(average, 58.4 and 55.2, respectively). To date, there have
been nine cases of recurrence in 450 patients treated for
gastric cancer (2%). In addition, no port-site recurrences
have been reported.
Discussion
Laparoscopic surgery is becoming increasingly popular as
a viable option for the management of gastric cancer in the
Fig. 3 Completion of radical D2 lymph node dissection. LGA, left
gastric artery; PHA, proper hepatic artery; CHA, common hepatic
artery
Fig. 4 Complete dissection of #11d lymph node dissection. SpA,
splenic artery
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appeal, laparoscopic gastrectomy for curable gastric cancer
with lymph node metastasis remains very controversial.
Laparoscopic D2 lymph node dissection is technically
difﬁcult, and many surgeons have indicated that the pro-
cedure at station nos.12a, 14v, 11p, and 11d is difﬁcult and
hazardous. However, our experience has been decidedly
different. In fact, we found these dissections to be both
feasible and technically safe. Although the question arises
whether our laparoscopic D2 dissection is really an en bloc
dissection or not. Our lymph node dissection is not a
‘‘pickup dissection,’’ but rather, a complete lymphatic tis-
sue ‘‘en bloc dissection’’ equivalent to an open surgery.
Laparoscopic surgery for the treatment of advanced
gastric cancer also must consider the phenomenon of port-
site recurrences as well as the important radical lymph
node dissection. Port-site recurrences need further clariﬁ-
cation, but investigators have speculated that they probably
are caused by some combination of the following factors:
tumor manipulation, failure to isolate the tumor, and
forceful extraction of the surgical specimen. The literature
has yet to report any such recurrences after laparoscopic
radical gastrectomies. Moreover, we have not experienced
port-site recurrences after laparoscopic gastrectomy for
gastric cancer. Therefore, from this experience, our
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roscopically is safe and feasible for the treatment of curable
advanced gastric cancer. However, the current practice of
laparoscopic surgery for curable gastric cancer with lymph
node dissection should be conﬁned to experienced surgeons
due to insufﬁcient elucidation of port-site recurrence
mechanisms. Furthermore, randomized controlled studies
are needed in this ﬁeld.
Although a substantial number of cases and randomized
control studies are necessary for an objective evaluation of
our procedure’s beneﬁt and curability potential, we believe
that laparoscopic surgery for curable gastric caner is both
technically feasible and safe and has many advantages over
conventional surgery. The laparoscopic approach is asso-
ciated with minimal postoperative pain, quick mobiliza-
tion, short hospital stay, and better cosmesis.
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